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IgE plays a central role in the pathogenesis of immediate hypersensitivity reactions 
through interacting with its receptors, in particular the high affinity receptor FcεRI. The 
low-affinity IgE receptor, CD23, affects IgE-dependent immune responses by regulating 
the synthesis of IgE, facilitating allergen presentation to the immune system, and 
influencing the activation and differentiation of B- and T-cells. Surprisingly, CD23 is 
different from other Ig receptors and belongs to the C-type (calcium-dependent) lectin 
family. Calcium binding to CD23 affects IgE binding to CD23, but previous NMR and 
crystal structures of CD23 gave conflicting results concerning the calcium binding sites. 
Investigation of calcium binding site(s) in CD23 and its complexes may assist CD23-
targeted drug design.  
 
DerCD23 (a fragment of human CD23 that consists of the lectin domain and part of the 
C-terminal tail) and derCD23 mutants designed to remove each of the two potential 
calcium binding sites, were expressed and purified. The crystal structures of Ca2+-bound 
wild type derCD23, the complex with the Fcε3-4 sub-fragment of IgE-Fc, and four 
putative calcium binding site mutants of derCD23 were solved. Binding affinities of 
derCD23 and its mutants for calcium and for IgE-Fc were measured with ITC and SPR. 
The results indicate a loop of derCD23 (loop 4) is stabilized upon calcium binding to 
“site 2” and thereby contributes to the increased binding affinity for IgE. In addition, a 
residue (D258) in the non-conserved “site 1” is observed to bind IgE directly in the 
Ca2+-bound derCD23/Fcε3-4 complex. Thus, Ca2+ bound to site 2 in CD23 stabilizes 
loop 4 for IgE binding, whereas site 1 has evolved to bind IgE directly.  
 
Clinical studies of IDEC152 (also known as Lumiliximab), a primatized IgG1, anti-
CD23 monoclonal antibody (IDEC Pharmaceuticals, San Diego, CA) show positive 
clinical effects in patients with allergic asthma and chronic lymphocytic leukemia. The 
Fab fragment of IDEC152 was prepared by enzymatic digestion from IDEC152 and 
crystals of the complex of derCD23 with IDEC152-Fab were grown, which diffracted to 
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The term allergy was introduced about one hundred years ago (Jackson, 2001). Allergy 
is a modern disease that is mainly found in developed countries. The type I 
hypersensitivity reaction is caused by harmless environmental substances and results in 
an inflammatory response. Although scientists and clinicians have developed many 
approaches to combat this disease, the number of patients with this disease is still 
increasing. Reasons for the increase may be excessive cleanliness, severe virus 
infections, vaccinations and pollution, although it is still unclear.  
 
IgE plays an important role in allergic disease (Sutton and Gould, 1993). There are two 
principal receptors for it: FcεRI (high-affinity Fc receptor) and FcεRII or CD23 (low-
affinity Fc receptor). Although structures of IgE-Fc and interactions with FcεRI have 
been well characterised (section 1.2.2), there is no structural study of the CD23/IgE 




1.2.1 IgE in allergy and asthma  
 
It is well established that the role of IgE in allergic diseases is mediated through its 
interactions with two receptors: FcεRI and CD23. The central function of IgE is 
performed by interaction with FcεRI on mast cells, APCs (antigen-presenting cells) in 
mucosal tissues and basophils in the blood. The synthesis of IgE in B cells follows 
heavy-chain class switching from IgM to IgE, either directly or via IgG. On mast cells 
and basophils, crosslinking of the FcεRI-bound IgE by allergen mediates immediate 
hypersensitivity that is the hallmark of an allergic response. Cytokines and chemokines 
Chapter 1  Introduction 	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are liberated and involve recruitment and activation of inflammatory cells. Crosslinking 
of the FcεRI-bound IgE by allergen on APCs, which express both FcεRI and CD23, 
leads to the presentation of allergen to the immune system. TH2 cells and mast cells 
produce IL-4, IL-13 and CD40L, which in turn promote IgE synthesis by B cells 
(Figure 1.1) (Gould and Sutton, 2008). The low-affinity receptor of IgE, CD23 is 
involved in regulating IgE synthesis and the processing of allergen for presentation of 











Figure 1.1 Pathway of IgE-mediated allergic responses. 
Expression of IgE by B cells requires heavy-chain class switching from IgM to IgE. Secreted 
IgE binds to FcεRI on mast cells, basophils and APCs to sensitize these cells (a and b). Allergen 
crosslinks FcεRI-bound IgE on mast cells and triggers degranulation to cause allergic responses 
(c). Crosslinking of FcεRI-bound IgE by allergen on APCs leads to the presentation of allergen 
to the immune system (d). TH2 cells secreted interleukin-4 (IL-4) is involved in maintaining the 
TH2 lineage and recruiting more TH cells into the lineage (e). TH2 cells and mast cells produce 
IL-4, IL-13 and CD40L, and stimulate heavy-chain class switching to IgE and expression of 
CD23 (f, g and h). Human CD23 regulates IgE synthesis through interaction with CD21 (i). 
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1.2.2 Structures of IgE 
 
1.2.2.1 Domain structures of IgE 
    
As one of five major antibody isotypes (IgA, IgD, IgE, IgG, and IgM) found in 
mammals, IgE was named in 1968 (Stanworth, 1993). IgE exists in both soluble and 
membrane-bound form. The membrane-bound form of IgE contains an additional 
extracellular membrane proximal domain (EMPD) and transmembrane sequence 
compared to the soluble IgE (Bestagno et al., 2001; Gould and Sutton, 2008). Soluble 
IgE consists of two heavy chains and two light chains, and the heavy ε-chain contains 
one more immunoglobulin domain than the γ-chain of IgG (Figure 1.2) (Gould and 
Sutton, 2008).  
 
IgE consists of an Fc region (Cε2, Cε3, Cε4) and two identical Fab fragments. IgE-Fc 
has the ability to bind two receptors (FcεRI and CD23), whereas the Fab sub-fragment 
is the antigen-binding fragment. IgE-Fc can be truncated to produce smaller fragments 
for structural study, such as Fcε3-4, and the Cε3 and Cε2 domains. Fcε3-4 consists of 
only the Cε3 and Cε4 domains as a disulphide-linked dimer. The disulphide bridge 
(between residues 328 in each chain) in Fcε3-4 does not exist in the full IgE-Fc, which 
has two “crossed” disulphide bridges between residues 241 and 328 (Section 1.2.2.3). In 
contrast, the hinge regions of IgG subclasses contain parallel disulphide bridges, and 
intra-chain disulphides in the hinge of some IgG4 immunoglobulins (Aalberse and 
Schuurman, 2002; Kessler et al., 1991). The high mannose type carbohydrate 
composition of the IgE-Fc is not required for binding to receptors (Basu et al., 1993; 
Bjorklund et al., 1999; Geha et al., 1985; Helm et al., 1988). This is also different from 
the high dependence of receptor binding on the complex-type glycosylation in IgG 
(Mimura et al., 2001; Tao and Morrison, 1989).  




Figure 1.2 Schematic representations of the domain structures of human IgE and IgG. 
IgE-Fc consists of Cε2, Cε3 and Cε4. IgE-Fc can be truncated to produce smaller fragments for 
structural study, such as Fcε3-4, and the Cε3 and Cε2 domains. IgG-Fc has only two domains 
(Cγ2 and Cγ3) and a flexible hinge which takes the place of the Cε2 in IgE. Disulphide bridges 
and sites of N-linked glycosylation are indicated as black lines and dots, respectively. (Figure 
adapted from Gould and Sutton 2008) 
 
1.2.2.2 Structure of Fcε3-4  
 
The crystal structure of Fcε3-4 confirms that this domain pair is homologous to Fcγ2-3 
in the IgG-Fc. However, Fcε3-4 appears much more compact than the Fcγ2-3 as a result 
of a smaller angle between Cε3 and Cε4 (Wurzburg et al., 2000). Comparison of this 
single Fcε3-4 molecule (closed) with the one (open) in complex with FcεRI reveals a 
conformational flexibility (Figure 1.3). Fcε3-4 also exhibits flexibility within Cε3, 
compared with less structural flexibility of Cγ2 in Fcγ2-3. 






Figure 1.3 Surface representation of the “closed” and “open” conformations of Fcε3-4 
structures (PDB code 1FP5 and 1F6A). 
 A: Side view of the “closed” conformation of uncomplexed Fcε3-4 and “open” conformation in 
complex with FcεRI (FcεRI not shown). B: Top view of “closed” and “open” conformations of 
Fcε3-4 structures. FcεRI-binding residues are coloured as magenta. (Figure taken from 
Wurzburg et al., 2000) 
 
 
1.2.2.3 Structure of IgE-Fc 
 
The structure of Cε2 was solved by nuclear magnetic resonance (NMR) after 
publication of the crystal structure of Fcε3-4. A combination of this structure with 
biophysical studies revealed many clues to the role of Cε2 domain in allergic reactions 
(McDonnell et al., 2001). Then the structure of the IgE-Fc was determined by X-ray 
crystallography (Wan et al., 2002). The IgE-Fc structure has one Cε2 domain that 
makes extensive contacts with both Cε3 and Cε4 domains, whereas the other Cε2 has 
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few contacts with Fcε3-4 (Figure 1.4). The acutely bent conformation of IgE-Fc 
confirms previous analytical ultracentrifuge results showing one Cε2 binding to one 
Fcε3-4 (McDonnell et al., 2001). The interface between the two Cε2 domains is 
different to the earlier predicted models (Helm et al., 1991; Padlan and Davies, 1986). 




Figure 1.4 Structure of IgE-Fc (PDB code 1O0V). 
Front and side views of IgE-Fc in cartoon and schematic representation. Inter-chain disulphides 
are shown in yellow. (Figure taken from Wan et al., 2002) 
 
Comparison of the IgE-Fc structure with uncomplexed and complexed Fcε3-4 reveals 
further asymmetry. The Fcε3-4 region of IgE-Fc adopts a conformation that differs from 
both the “closed” and “open” conformations (Figure 1.5). One Cε3 domain in IgE-Fc 
adopts a “closed” conformation by contact with a Cε2 domain, whereas the other Cε3 
domain is in an “open” conformation. 
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Figure 1.5 Comparison of the Fcε3-4 region in the full IgE-Fc structure (PDB code 1O0V) 
with the “closed” and “open” conformations of Fcε3-4 (PDB code 1FP5 and 1F6A). 
Fcε3-4 of the IgE-Fc, “closed” and “open” Fcε3-4 structures are shown as blue, red and green 
respectively. (Figure taken from Wan et al., 2002) 
 
1.2.2.4 Structure of IgE-Fc in complex with FcεRI 
 
The complex of IgE-Fc with the soluble, extracellular domains of the α-chain of FcεRI 
was reported recently (Holdom et al., 2011). The FcεRI bound IgE-Fc has a more 
acutely bent structure than the structure of free IgE-Fc (Figure 1.6). Cε2 domains have 
no direct contact with the FcεRI in this even more acutely bent IgE-Fc structure. 
However, the non-contacting Cε2 domains enhance stabilization of the complex, which 
is supported by thermodynamic analysis (Holdom et al., 2011).  
 
Comparison of all free or FcεRI-bound IgE-Fc and Fcε3-4 structures reveal the 
flexibility of Cε3. As the binding site of both FcεRI and CD23 (Section 1.4.1), Cε3 
exhibits unusual flexibility that may be required for interaction with these two IgE 
receptors (Wurzburg et al., 2000).  




Figure 1.6 Comparison of the full IgE-Fc structure (PDB code 1O0V) with the IgE-Fc in 
IgE-Fc/FcεRI complex (PDB code 2Y7Q). 
The FcεRI bound IgE-Fc is more acutely bent than free IgE-Fc. A: Free IgE-Fc (with 
carbohydrate) is shown as yellow. FcεRI and FcεRI-bound IgE-Fc are shown as blue and purple 
respectively. B: Cε4 domains are hidden in this view. Free IgE-Fc, FcεRI and FcεRI bound IgE-





1.3.1 CD23 expression 
 
The low-affinity IgE receptor, CD23, was discovered over 30 years ago (Gonzalez-
Molina and Spiegelberg, 1976; Lawrence et al., 1975). There are two forms of CD23 
(CD23a and CD23b) that differ by 6 or 7 amino acids at the N-terminal (intracellular) 
sequence (Gould and Sutton, 2008; Yokota et al., 1988). They are present on various 
cell types, including macrophages, monocytes, eosinophils, platelets, follicular dendritic 
cells, B cells and T cells (Capron et al., 1981; Delespesse et al., 1991; Melewicz et al., 
1982; Sarfati et al., 1986). CD23 is also expressed on some epithelial cells (Billaud et 
al., 1989). In addition to expression in this wide range of cell types, CD23 is treated as a 
disease marker playing important roles in many different diseases: atopy, autoimmunity 
and chronic lymphocytic leukemia (Gordon, 1991). 
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1.3.2 Functions of CD23  
 
1.3.2.1 Regulation of IgE synthesis 
 
IgE-sensitized APCs bind allergen via FcεRI, but CD23 also facilitaes allergen 
presentation by binding IgE/allergen complexes; both processes lead to the presentation 
of allergen to T helper 2 (TH2) cells. This promotes IgE synthesis by B cells through 
producing IL-4 and IL-13 (Miescher and Vogel, 2002). TH2 cells express CD40L, 
which together with IL-4 promote IgE synthesis by stimulating heavy-chain class 
switching to IgE (Gould and Sutton, 2008).  
 
CD23 and CD21 molecules are also involved in regulating IgE synthesis (Bonnefoy et 
al., 1996; Gould and Sutton, 2008; Gould et al., 2003). CD23 plays a central role in IgE 
synthesis, and a model has been proposed as described below (Gould and Sutton, 2008) 
(Figure 1.7). A soluble, trimeric form of cleaved membrane CD23 upregulates IgE 
synthesis by co-ligation of membrane bound IgE and CD21 (Cooper et al., 2012). 
However, monomeric soluble CD23, cleaved by proteases such as Der p I (house dust 
mite protease), has opposite effects on IgE regulation (Bonnefoy et al., 1996; Gould et 
al., 2003; McCloskey et al., 2007). Membrane CD23 and membrane IgE are co-ligated 
by allergen-IgE complexes in negative signalling for IgE synthesis. Previous 
experiments using inhibitors of CD23 proteolysis and CD23-specific antibodies showed 
decreased IgE levels (Gould and Sutton, 2008; McCloskey et al., 2007; Rosenwasser 
and Meng, 2005). Thus, CD23 can be a promising therapeutic target for the treatment of 
allergic diseases.  
 
 




Figure 1.7 Positive and negative regulation of IgE by CD23. 
Co-ligation of membrane bound IgE and CD21 on a human B cell by soluble trimeric CD23 
leads to positive regulation of IgE synthesis. Membrane bound CD23 delivers a negative signal 
for IgE synthesis by the co-crosslinking of membrane CD23 and membrane IgE by an allergen-
IgE complex. EMPD: extra-cellular membrane-proximal domain. CD21, a member of the 
complement system, has domains 1-2 and 5-8 involved in the binding to CD23 (Section 1.5). 
(Figure taken from Gould and Sutton, 2008) 
 
1.3.2.2 Other functions of CD23 
 
APCs express both FcεRI and CD23, crosslinking of the FcεRI-bound IgE by allergen 
on APCs leads to the presentation of processed allergen to the T cells, and CD23 is 
involved in allergen presentation by facilitating internalisation of IgE-allergen 
complexes (Carlsson et al., 2007; Gould and Sutton, 2008). In addition, CD23 
contributes to the spreading of sensitivity to a single allergen to unrelated allergens in 
allergen presentation (Gould and Sutton, 2008; Mudde et al., 1995).  
 
CD23 also plays important roles in transporting allergen-IgE complexes across 
epithelial barriers in the gut and airways (Gould and Sutton, 2008; Palaniyandi et al., 
2011; Tu et al., 2005). CD23, expressed on intestinal or airway epithelial cells, captures 
allergen-IgE complexes on the luminal side and transports them into the mucosa. The 
transported allergen may then crosslink FcεRI-bound IgE on mast cells to cause 
degranulation, and on APCs to present allergen to the immune system. 
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CD23 is also involved in the germinal centre reaction to rescue selected B cells from 
apoptosis (Bonnefoy et al., 1993; Gould et al., 2003; Liu et al., 1991), and in monocyte 
activation in inflammation through interactions with CD18/CD11b and CD18/CD11c 
(Lecoanet-Henchoz et al., 1995). 
  
1.3.3 Structure of CD23 
 
1.3.3.1 Membrane bound CD23 and its soluble fragments 
 
This 45 kDa molecular weight type II integral membrane protein, whose carboxy-
terminus is outside the membrane, is different from other Ig receptors and belongs to the 
C-type lectin family (Kikutani et al., 1986; Kintner and Sugden, 1981; Thorley-Lawson 
et al., 1986). The C-type lectin family is a group of calcium dependent and carbohydrate 
binding proteins (Zelensky and Gready, 2005). The extracellular sequence of 
membrane-bound CD23 consists of an α-helical coiled-coil stalk, C-type lectin head 
domain, C-terminal tail and N-linked glycosylation (Figure 1.8) (Beavil et al., 1992; 
Gould and Sutton, 2008). The C-terminal tail is absent in the mouse form of CD23, 
which also has a shorter stalk region (Beavil et al., 1992). 
 
The stalk region can be cleaved to release soluble CD23 by various proteases, such as 
ADAM10 that is a disintegrin and metalloproteinase (Lemieux et al., 2007; Weskamp et 
al., 2006). CD23 can also be cleaved by the house dust mite allergen Der p I (Schulz et 
al., 1995). Monomeric derCD23, S156-E298 of the full-length CD23, is a recombinant 
protein corresponding to the fragment released by Der p I which contains the lectin 
domain and part of the C-terminal tail (Schulz et al., 1997). TriCD23 is a recombinant 
trimeric CD23 which consists of the lectin domain, C-terminal tail, part of the coiled-
coil stalk and a synthetic isoleucine zipper motif to form a high affinity trimer. 
Monomeric CD23 binds to IgE with relatively low affinity (KA ≈ 106-107 M-1) (Dierks 
et al., 1993), but trimeric CD23 binds to IgE with higher affinity (KA ≈ 108-109 M-1) 
(McCloskey et al., 2007; Hibbert et al., 2005). This avidity effect is due to the 
combined strength of multiple bond interactions through more than one head domain.  
 




Figure 1.8 A schematic presentation of membrane-bound CD23. 
The extracellular sequence of membrane-bound CD23 consists of an α-helical coiled-coil stalk, 
C-type lectin head domain, C-terminal tail and N-linked glycosylation. (Figure taken from 
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1.3.3.2 Three-dimensional structure of CD23 head domain 
 
Initially, the structure of the CD23 head domain was modelled based on the crystal 
structure of rat mannose binding protein (MBP) and E-selectin (Bajorath and Aruffo, 
1996; Padlan and Helm, 1993; Schulz et al., 1997). Then, the three-dimensional 
structure of derCD23 (the amino acids from S156 to E298 of human CD23) was solved 
by nuclear magnetic resonance (NMR) spectroscopy (Hibbert et al., 2005). The NMR 
structure consists of two α helices and eight β strands (Figure 1.9). With NMR titration 
experiments, chemical shifts suggest calcium “site 1” (Figure 1.10) is the calcium-
binding site, including backbone amides for I221, N225, K229, G230, E231, D270, 
A271, D274 and side-chain amide of N225 (Hibbert et al., 2005).  
 




Figure 1.9 Structure of derCD23 determined by NMR. 
A cartoon representation of the structure of derCD23 determined by NMR (PDB code 1T8D), 
with secondary structure identified. (Figure taken from Hibbert et al., 2005) 
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Figure 1.10 The calcium binding site in derCD23 (PDB code 1T8D).  
Gray region is the backbone of derCD23. Residues showing substantial chemical shifts in NMR 
titration experiments with calcium are indicated in yellow. Blue balls are two possible calcium 
binding sites. (Figure taken from Hibbert et al., 2005) 
 
 
Two crystal structures of human CD23 double mutant (residues 150-321, with two non-
silent mutations of H213R and G256S) were determined later by X-ray crystallography, 
one with calcium and one without calcium (Wurzburg et al., 2006). The crystal 
structure of the CD23 double mutant showed that residues E249, T251, N269 and D270 
bind to calcium (Figure 1.11) in contrast to the NMR structure, whereas residue R253 
occupies the calcium position in the calcium-free form of the CD23 structure. This 
indicates calcium “site 2”, which is labelled Ca2+ 2 in Figure 1.10, is the calcium-
binding site. Another unusual feature of the calcium-bound structure is the disordered 
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Figure 1.11 The calcium binding site. 
A: Calcium bound crystal structure of CD23 (PDB code 2H2T) indicates calcium (green ball) 
binds to residues E249, T251, N269 and D270. The beginning of missing loop 4 (253-257) is 
indicated with a black arrow. B: Residue R253 occupies the calcium position in the apo form of 





1.4 CD23 interactions with IgE 
 
1.4.1 CD23 interactions with IgE 
 
 It is clear that CD23 plays important roles through interaction with IgE in allergic 
disease (Gould and Sutton, 2008). Understanding of the CD23-IgE interaction may 
reveal many aspects of the mechanism of allergic disease and provide a possible target 
for therapeutic intervention. Although structures of IgE-Fc and CD23 head domain have 
been reported, no crystal structure has yet been solved for the CD23-IgE complex.  
 
The binding site of CD23 on IgE has been studied using a number of monoclonal 
antibodies or mutations. Binding of CD23 to IgE was not affected by antibodies that 
recognized the Cε4 domain or a spanning part of the Cε2 and Cε3 domains, but was 
inhibited by antibodies that recognized residues 367-376 of Cε3 domain (Chretien et al., 
1988). CD23 binding on the Cε3 domain was confirmed by a separate study using 
monoclonal antibodies against Cε2 and Cε3 domains (Vercelli et al., 1989). Keegan and 
coworkers found that antibodies directed at Cε3 and Cε4 prevent the CD23-IgE 
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interaction (Keegan et al., 1991). In addition, a single mutation of Lys352 on Cε3 
disrupted the CD23-IgE interaction completely (Sayers et al., 2004). Therefore, the 
binding site of CD23 on IgE is believed to be within Cε3 domain. 
 
The first indication of the IgE binding site on CD23 came in 1989, with mutagenesis 
and monoclonal antibody binding studies which suggested that residues 165-190 and 
224-256 were involved (Bettler et al., 1989; Bettler et al., 1992). In addition, NMR 
titration experiments by adding Cε3 to isotopically labelled derCD23 showed residues 
in the CD23 head domain that were involved in binding to IgE (Hibbert et al., 2005). 
Ultracentrifugation data indicate that both IgE-Fc and Fcε3-4 bind CD23 with a 2:1 
stoichiometry (McCloskey et al., 2007; Shi et al., 1997).  
 
 
1.4.2 The role calcium plays in CD23 binding to IgE 
 
C-type lectin-like domains (CTLDs) are a large group of proteins with diverse 
functions. Mannose binding protein (MBP) is a C-type lectin that possesses a calcium-
dependent carbohydrate-binding activity (Weis et al., 1992). Calcium-dependent 
structural changes in this protein are well understood, and provide a good model to 
investigate the role calcium plays in other CTLDs. Calcium stabilizes the structure of 
loops in MBP that are essential for carbohydrate-binding (Ng et al., 1998; Ng and Weis, 
1998).  
 
Unlike MBP, CD23 appears to have lost the function to bind carbohydrate, and 
carbohydrate is not required for CD23 binding to IgE (Hibbert et al., 2005; Vercelli et 
al., 1989). However, it was reported that the binding of IgE to CD23 is calcium-
dependent (Richards and Katz, 1990). Calcium increases CD23 binding affinity to IgE 
in SPR experiments 7-fold (Hibbert et al., 2005). NMR titration experiments showed 
that residues I221, N225, K229, G230, E231, D270, A271 and D274 displayed 
substantial chemical shifts after binding with calcium, while residues W184, R188, 
Y189, A190, L198, H202, I221, G222, R224, N225, L226, W234, V235, A271, C273, 
D274, K276, and A279 in derCD23 were involved in binding to the Cε3 domain of IgE 
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(Hibbert et al., 2005). The chemical shifts of some residues were observed in both 
experiments. According to the two crystal structures and mutagenesis study (Bettler et 
al., 1992) of CD23, loop 1 (226-231) and loop 4 (253-257) are the overlap regions of 
calcium binding and IgE binding (Figure 1.12) (Wurzburg et al., 2006). Taking all this 
evidence together, calcium is believed to be involved in IgE binding. However, loop 4 is 
disordered in the calcium-bound structure of CD23 double mutant (Figure 1.11A). This 
is inconsistent with the role of calcium in stabilizing the loop as seen in other CTLDs 




Figure 1.12 overlap regions of calcium binding and IgE binding. 
Blue: regions implicated in IgE binding by mutagenesis study. 
Red: residues whose positions are different in the apo and calcium bound form of CD23 (PDB 
code 2H2R and 2H2T). Magenta: the overlap regions of calcium binding and IgE binding. 






CD21, depicted in Figure 1.7, also known as complement receptor type 2 (CR2), 
belongs to the complement system, a family of soluble proteins and cell surface 
receptors (Roozendaal and Carroll, 2007). This membrane protein functions as counter-
receptor for CD23 to regulate IgE synthesis in the network of allergic disease (Aubry et 
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al., 1992; Sutton and Gould, 1993). Domain1 and Domain2 (D1D2), and also D5-D8 
have been implicated in IgE binding (Aubry et al., 1992). N-linked carbohydrates on 
domains 5 to 8 of human CD21 were reported to be involved in the CD23/CD21 
interaction (Aubry et al., 1994). The binding surface for CD21 D1D2 on derCD23 has 
already been mapped at the start of the “tail” (residues E294, G295, S296 and E298)  by 
NMR titration experiments (Hibbert et al., 2005). Although there are already crystal 
structures of domains D1 and D2 of CD21 (Prota et al., 2002; Szakonyi et al., 2001), 
the complex structure of CD21 with CD23 has not been reported. Since CD23 binds to 
both CD21 and IgE, it has been hypothesised that CD23 regulates IgE synthesis by 
forming IgE-CD23-CD21 trimolecular complex on a human B cell (Figure 1.7) (Gould 





IDEC152 (also known as Lumiliximab) is a primatized, IgG1, anti-CD23 monoclonal 
antibody (IDEC Pharmaceuticals, San Diego, CA). In clinical trials this antibody 
resulted in sustained and dose-dependent decreases in serum IgE concentrations 
(Rosenwasser et al., 2003). It was also reported that IDEC152 inhibited allergen-
induced responses in antigen-presenting cells and T cells (Poole et al., 2005). Thus, it is 
a potential therapeutic antibody for the treatment of allergic asthma. What is more, 
IDEC152 is promising therapy for chronic lymphocytic leukemia through binding to 
CD23 (Byrd et al., 2007; Mavromatis and Cheson, 2004). Nothing is known of the 
IDEC152 binding site on CD23, or any structural details of its mechanism of action. 
 
1.7 Aims of project 
 
a) Although three-dimensional structures of CD23 and IgE have been reported, there are 
still many important issues concerning the two proteins, which need to be described 
clearly. Understanding of CD23 and its complexes may lead to CD23-targeted drug 
design. However, there is a controversy concerning the location of the calcium binding 
site(s) in CD23, and their roles in IgE binding. The calcium binding sites in the NMR 
and crystal structures are different from each other. Although it was reported that the 
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binding of IgE to CD23 is calcium-dependent (Richards and Katz, 1990), there is no 
three-dimensional structure of the complex to support it. Thus, determining the calcium-
binding site of CD23 can help to study the interaction of IgE and CD23. Mutants of 
derCD23 have been designed to probe the calcium binding site(s) for expression, 
biophysical analysis by ITC, SPR and for X-ray structure determination. 
 
b) The structures of Fcε3-4 and IgE-Fc with FcεRI (high-affinity receptor) have been 
determined and exploited for the development of inhibitors of allergic disease (Garman 
et al., 2000; Holdom et al., 2011). CD23 is important in the regulation of IgE synthesis 
(Gould and Sutton, 2008). Thus, determining the structure of Fcε3-4 or IgE-Fc with 
CD23 may also provide a structural basis for anti-allergy drug design. Because CD23 
binds to the Cε3 domain of IgE-Fc (Section 1.4.1), it is possible to attempt to crystallise 
the complex of derCD23 with the Fcε3-4 part of IgE-Fc. 
 
c) CD23 is a disease marker in atopy, autoimmunity and chronic lymphocytic leukemia. 
IDEC152 (Lumiliximab) is a primatized, IgG1, anti-CD23 monoclonal antibody. 
Clinical trials of IDEC152 indicated therapeutic action in allergy and chronic 
lymphocytic leukemia. Thus, co-crystallisation of IDEC152-Fab with derCD23 will 
reveal the mechanism of its therapeutic action in allergy and chronic lymphocytic 
leukemia.  
 








2.1.1 Chemicals, reagents 
 
1,6-Hexanediol (Sigma-Aldrich) 
Acrylamide/Bis-acrylamide (Severn Biotech Ltd) 
Ammonium persulfate (Sigma-Aldrich) 
Ammonium sulfate (Sigma-Aldrich) 
Ampicillin (Sigma-Aldrich) 
Bis-tris-propane (Sigma-Aldrich) 









Human IgG (Sigma-Aldrich) 
Immobilized Papain slurry (PIERCE) 
Isopropyl β-D-1-thiogalactopyranoside (Sigma-Aldrich) 
LB agar powder (Invitrogen) 
LB powder (Invitrogen) 
MES (Sigma-Aldrich) 
NaCl (Sigma-Aldrich) 
Oxidized glutathione (Sigma-Aldrich) 
PEG (Fluka) 
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Pyridinio propanesulfonate (Sigma-Aldrich) 
Potassium thiocyanate (Sigma-Aldrich) 
Reduced glutathione (Sigma-Aldrich) 
SDS (Severn Biotech Ltd) 
SeeBlue® Plus2 molecular weight marker (Invitrogen) 
Sodium azide (Sigma-Aldrich) 





Trizma base (Sigma-Aldrich) 
Fcε3-4 was obtained from Dr. Alistair Henry, UCB 
 
2.1.2 Buffers, solutions and media 
 
Coomassie staining buffer: 0.25% coomassie brilliant blue, 7.5% acetic acid, 5% 
methanol in ddH2O 
Gel de-staining buffer: 10% acetic acid, 40% methanol in ddH2O 
Gel running buffer: 25 mM Tris pH 8.8; 200 mM glycine; 0.1% (w/v) SDS 
Heparin loading buffer: 25 mM Tris pH 7.5  
Heparin elution buffer: 25 mM Tris pH 7.5, 200 mM NaCl 
NMR buffer: 10 mM Tris pH 6.8, 125 mM NaCl, 4 mM calcium chloride 
ITC buffer: 10 mM Tris pH 6.8, 125 mM NaCl 
Sample buffer for SDS-PAGE: 10% w/v SDS, 10 mM Dithiothreitol, or beta-mercapto-
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2.2 DNA metheds 
 
2.2.1 Plasmid vectors 
 
The E.coli strain BL21(DE3) containing pET5a-derCD23 vector was obtained from 
Prof. James McDonnell. The pET5a vectors containing derCD23 mutants (E249A, 
S252A, D258A, D270A) were provided by Dr. Balvinder Dhaliwal.  
 
2.2.2 Site directed mutagenesis 
 
Site directed mutagenesis of derCD23 to produce the mutants N269A and N269D was 
carried out using QuickChange kit (Stratagene, CA, USA) according to provided 
protocol. The primers that were used are listed in Table 2.1.  
 
N269A forward GGC TCC GGT CGC TGG GCC GAC GCC TTC TGC GAC 
N269A reverse GTC GCA GAA GGC GTC GGC CCA GCG ACC GGA GCC 
N269D forward GGC TCC GGT CGC TGG GAC GAC GCC TTC TGC GAC 
N269D reverse GTC GCA GAA GGC GTC GTC CCA GCG ACC GGA GCC 





Transformations were performed using BL21(DE3) competent cells (New England 
Biolabs). 50 microliters cells were thawed on ice and 1 microliter DNA added as soon 
as the last piece of ice in the tube disappeared. For maximum transformation efficiency, 
cells and DNA were incubated together on ice for 30 minutes, and then heated for 10 
seconds at 42°C. Then cells were grown at 37°C with shaking for 1 hour for cell 
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2.2.4 Plasmid purification  
 
Single colonies were picked and grown in 5 ml LB medium (Section 2.3.1) in a 50 ml 
flask with shaking (200 rpm) overnight at 37°C. Cell culture was spun down at 12000 
rpm in a microcentrifuge and the plasmid DNA was purified using Qiagen plasmid 
purification Mini Kit. DNA concentration was measured with a NanoDrop ND-1000 
Spectrophotometer.  
 
2.2.5 DNA sequencing 
 
Samples to be sequenced were sent to Source BioScience LifeSciences for analysis. 
 
2.3 Protein expression in E.coli 
 
2.3.1 LB culture medium 
 
20 g LB powder (Invitrogen) was added in MilliQ water and the volume was adjusted to 
1 liter. Then the solution was autoclaved. The medium was stored at room temperature. 
Concentration of Ampicillin (Sigma-Aldrich) was adjusted to 100 µg/ml before use. 
 
2.3.2 LB agar culture plates 
 
16 g LB agar powder (Invitrogen) was added to MilliQ water and the volume was 
adjusted to 1 liter. After being autoclaved, the solution was cooled to approximately 
55°C before addition of ampicillin (Sigma-Aldrich) to 100 µg/ml, and poured into 90 
mm diameter Petri dishes (15 ml per dish). Plates were stored in plastic bags at 4°C. 
 
2.3.3 Long term storage of bacterial strains 
 
For each strain to be stored at -80°C, 225 µl sterile 80% glycerol was added into the 
eppendorf tube and 1.0 ml of the bacterial culture (frozen stock was therefore at 15% 
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glycerol). Each tube was mixed well (vortexed) and placed at -80°C. The viability of the 
cells was checked after 1 week. 
 
2.3.4 Protein expression of derCD23 and derCD23 mutants  
 
1 litre culture of E. coli BL21 (DE3) cells harbouring the derCD23 gene was grown at 
37°C in a shaking flask with LB medium. When the culture reached A600nm = 0.6-0.7, 
the lac promoter was induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside 
(IPTG). After 3 hours induction, cells were harvested by centrifugation at 8000 rpm for 
20 minutes in a JLA-8.1000 rotor. Cell pellets were resuspended in 30 ml 25 mM Tris 
pH 7.5 and stored at -20°C. 
 
2.4 Refolding of derCD23 and derCD23 mutants 
 
Cell pellets in resuspension buffer (25 mM Tris pH 7.5) were thawed and Triton X-100 
was added to a final concentration of 1%. The mixtures were sonicated in 8 bursts of 1 
minute each with breaks of 30 seconds. Samples were centrifuged at 12000 rpm and 
4°C for 10 minutes in a SS34 Sorvall rotor. The pellets were resuspended in 25 mM 
Tris pH 7.5 and centrifuged at 12000 rpm in a SS34 Sorvall rotor and 4°C with slow 
shaking overnight. The pellet were resuspended in 25 mM Tris pH 7.5, 0.5 M GuHCl 
and centrifuged at 12000 rpm in a SS34 Sorvall rotor and 4°C for 10 minutes. Finally 
the pellet was resuspended in solubilisation buffer (25 mM Tris pH 7.5, 6 M GuHCl) 
and dissolved overnight with slow shaking.  
 
3.5 ml of protein sample in solubilisation buffer was further diluted with solubilisaition 
buffer to a total volume of 15 ml, and 7.5 µl 1 M DTT was added to the protein sample. 
The protein sample was diluted into 150 ml refolding buffer (1 M pyridinio 
propanesulfonate, 10 mM Tris pH 8.0, 1 mM CaCl2 with 0.98 mM oxidized glutathione, 
0.65 mM reduced glutathione) as slowly as possible with rapid stirring. Then the protein 
sample was stored at 4°C for 2 hours. NaCl was added to a final concentration of 50 
mM and the mixture was left at 4°C for 2 hours. The protein sample was dialysed into 2 
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litres of 20 mM Tris pH 7.5 overnight with one buffer change after 14 hours and 
dialysis for a further 3 hours. 
 
2.5 Purification of derCD23 and derCD23 mutants 
 
2.5.1 Heparin-sepharose chromatography  
 
The HiPrep heparin column (GE Healthcare) was washed with 40 ml of 2 M NaCl, 40 
ml water at a flow rate of 3 ml/min, and equilibrated with 100 ml of heparin loading 
buffer (25 mM Tris pH 7.5). The protein sample (derCD23) was dialyzed into heparin 
loading buffer. After being filtered with an 0.45 µm filter, the protein sample was 
loaded onto the heparin column (GE Healthcare) at 2 ml/min with a pump, connected to 
an AKTA-FPLC (GE Healthcare). The column was washed with 100 ml heparin 
loading buffer until the UV baseline was stable, and eluted with 50 ml of heparin 
elution buffer (25 mM Tris pH 7.5, 200 mM NaCl). Fractions containing the protein 
were collected into 15 ml tubes. The column was cleaned thoroughly every two weeks. 
The flow direction of the column was reversed and washed at a flow rate of 1 ml/min 
with 50 ml of 6 M Guanidine hydrochloride. Then the column was washed with 40 ml 
water, 40 ml of 0.1 M NaOH, 40 ml water and left in 20% ethanol.  
 
2.5.2 Gel filtration chromatography 
 
The HiLoad 16/60 Superdex G75 column (GE Healthcare) was equilibrated with gel 
filtration buffer (25 mM Tris pH 7.5) at a flow rate of 1 ml/min. Protein samples eluted 
from the heparin column were concentrated to 1 ml and applied onto the Superdex G75 
column, which was washed with gel filtration buffer. After concentrating the fraction 
containing derCD23, the protein concentration was 10 mg/ml in 25 mM Tris pH 7.5. 
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2.5.3 Buffer exchange  
 
Buffer exchange was performed by dialysis using dialysis tubing (Fisher Scientific Ltd) 
with a molecular weight cut-off at 10 kDa.  
 
2.5.4 Concentration methods 
 
Protein samples were concentrated using Amicon® Ultra-15 centrifugal filter devices 
(Millipore) at 4000 rpm in a PK121R centrifuge, ALC. The devices contained cellulose 
membranes with a molecular weight cut-off at 10 kDa. 
 
2.6 Protein characterization 
 
2.6.1 Estimation of protein concentration 
 
Protein concentration was measured with a NanoDrop ND-1000 Spectrophotometer at 
280 nm wavelength. Predicted extinction coefficients for derCD23 is 2.82 mg/(ml.cm), 




SDS-PAGE was used throughout the protein purification to assess the quantity and 
quality of protein (Laemmli, 1970) using a mini gel apparatus (BioRad). Gels were 
made according to the quantities of solutions listed in Tables 2.2 and 2.3. Samples were 
mixed in a ratio of 4:1 (protein: sample buffer), boiled for 10 minutes at 100°C and then 
spun for 10 minutes at 12000 rpm in a microcentrifuge. Protein samples were loaded 
along with SeeBlue® Plus2 molecular weight marker (Invitrogen). Gels were run at 
160V in gel running buffer until the dye reached the bottom. Gels were stained in 
Coomassie staining buffer for 40 minutes and de-stained in gel de-staining buffer 
overnight until protein bands were visible.  
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 7% 10% 12% 15% 
H2O 15.3 ml 12.3 ml 10.2 ml 7.2 ml 
1.5 M Tris pH 8.8 7.5 ml 7.5 ml 7.5 ml 7.5 ml 
20% (w/v) SDS 0.15 ml 0.15 ml 0.15 ml 0.15 ml 
Acrylamide/Bis-acrylamide 
(30%/0.8% w/v) 
6.9 ml 9.9 ml 12.0 ml 15.0 ml 
10% (w/v) ammonium persulfate 
(APS) 
0.15 ml 0.15 ml 0.15 ml 0.15 ml 
TEMED 0.02 ml 0.02 ml 0.02 ml 0.02 ml 
Table 2.2 Running gel. 
 
H2O 3.075 ml 
0.5 M Tris pH 6.8 1.25 ml 




10% (w/v) ammonium persulfate (APS) 0.025 ml 
TEMED 0.005 ml 
Table 2.3 Stacking gel. 
 
 
2.6.3 1D NMR spectroscopy 
 
One dimensional NMR spectroscopy data can be acquired in a short time and give 
information about the folded state of the protein. Protein samples were dialyzed into 10 
mM Tris pH 6.8, 125 mM NaCl, 4 mM calcium chloride and 5% D2O. Then the 
samples were spun at 12000 rpm in a microcentrifuge for 15 minutes to remove 
precipitations. The concentrations of derCD23 and mutants were adjusted to about 1 
mg/ml and the volumes were about 0.5 ml. Samples were placed in a Shigemi NMR 
tube (Sigma-Aldrich). The folding of derCD23 and mutants were checked at a proton 
frequency of 500MHz at 35°C.  
 
Chapter 2  Materials and methods 	  
 46 
2.7 Isothermal Titration Calorimetry (ITC) 
 
Isothermal Titration Calorimetry (ITC) is a technique to measure biomolecular 
interactions, including protein-small molecule, protein-protein, drug target-drug, 
enzyme-inhibitor, antibody-antigen, protein-DNA, protein-lipid and small molecule-
small molecule. ITC can accurately determine thermodynamic parameters (KA, KD, ∆S 
and ∆H) associated with binding. The principle of ITC is to use a cell feedback network 
to differentially measure and compensate for heat produced or absorbed between the 
sample and reference cell (Figure 2.1). ITC 200 apparatus (GE Healthcare) was used in 
the experiment. 1 litre of ITC buffer (Section 2.1.2) was treated by adding 50 g Chelex 
100 (Sigma) to remove calcium. Protein samples were dialyzed against 10 mM Tris pH 
6.8, 125 mM NaCl, 10 mM EDTA, then against Chelex 100 treated ITC buffer. 400 µl 
of 50 µM protein solutions were used for ITC experiments, and for the calcium 
titrations 20 mM calcium chloride in ITC buffer was used for injection at 25°C.  
 
 
Figure 2.1 The principle of ITC.  
Heat is generated or absorbed if there is a chemical reaction or interaction that occurs in the 
sample cell. Thermoelectric devices measure the temperature difference (∆T1) between the two 
cells and the temperature difference (∆T2) between the cells and the jacket respectively. The 
temperature difference (ΔT1) is kept the same by the addition or removal of heat to the sample 
cell. The recorded signal shows in the form of a peak, and parameters of binding are calculated 
from these signals recorded as a function of the titration of reactants.  
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2.8  Surface Plasmon Resonance (SPR) 
 
SPR is a technique to analyze the kinetics and thermodynamics of biomolecular 
interactions without the need to label reactants. Binding of molecules can be measured 
as a resonance signal as a function of time by detecting shifts in the angle of reflected 
light (Figure 2.2). BiacoreTM T200 equipment (GE Healthcare) was used in the 
experiment. 
 
Figure 2.2 The principle of SPR. 
SPR detects changes in the refractive index of the medium near the surface caused by binding of 
molecules (Cooper, 2002). Angle shifts of the reflected light (lower left-hand diagram) can be 
monitored and plotted as resonance signal versus time (lower right-hand diagram). (Figure 
taken from Cooper, 2002). 
 
All experiments were performed at 25°C. A specific binding surface was prepared by 
coupling derCD23 to a CM5 sensor chip through the amine coupling procedure. 
Coupling densities of 50 resonance units were used. Protein samples in HBS (10 mM 
Hepes, pH 7.4, 150 mM NaCl, 4 mM CaCl2, and 0.005% (vol/vol) surfactant p20) were 
injected over the sensor chip at 15 µl/min with a 90 s association phase followed by a 10 
minutes dissociation phase. In the reverse binding experiment, a biotinylated Fcε3-4 
protein was immobilized at 150 resonance units on a streptavidin chip, and soluble 
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derCD23 or mutants were injected over the surface. Biotinylation of Fcε3-4 was 
performed by mixing Fcε3-4 with Biotinamidohexanoic acid 3-sulfo-N-
hydroxysuccinimide ester sodium salt (Sigma-Aldrich) at a ratio of 3:1, a process that 
generally ensures a single biotinylation site per protein, followed by dialysis. Injections 
over underivatized sensor surfaces were performed to test for non-specific binding. 
Curve fitting and other data analyses were performed using MicroCal Origin 6.1 
(OriginLab Corporation). 
 
2.9 Preparation of IDEC152-Fab 
 
2.9.1 Antibody digestion 
 
10 mg IDEC152 IgG antibody was dialyzed into sample buffer (20 mM sodium 
phosphate, 10 mM EDTA, pH 7.0) and concentrated to approximately 20 mg/ml (0.5 
ml). The digestion buffer was prepared by adding a final concentration of 20 mM 
cysteine/HCl to the sample buffer and adjusting the pH to 7.0. Immobilized papain 
beads were mixed by inversion or gentle shaking to obtain an even suspension. Then 0.5 
ml of the 50% immobilized papain slurry was added to an Eppendorf tube. To ensure 
proper gel slurry dispensing, a cut pipette tip was used. 1.0 ml of digestion buffer was 
added to the gel slurry in order to equilibrate the gel. The gel was separated from the 
buffer by centrifugation. This wash procedure was repeated 3 times and the gel was 
resuspended in 0.5 ml of digestion buffer. 0.5 ml of the prepared sample was added to 
0.5 ml of digestion buffer and transferred to the eppendorf tube containing the 
immobilized papain.  
 
The mixture was incubated in a circulating water bath at 37°C at high flow rate with 
250 microliter samples for 30 min, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 
overnight. 0.25 ml of 10 mM Tris pH 7.5 was added to end the reaction. Constant 
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2.9.2 Ion exchange chromatography 
 
A TSKgel SP-5PW glass column (Tosoh Bioscience) was equilibrated with buffer A 
(20 mM sodium acetate pH 5.06). Protein samples digested from IDEC152 were 
dialysed into buffer A and then applied onto the ion exchange column, which was 
washed with buffer A. Then the proteins were eluted with a sodium chloride gradient 
elution using 10 times column volume. Peaks were collected after buffer B (20 mM 
sodium acetate pH 5.06, 200 mM NaCl) reached 100%.  
 
2.10 Crystallisation and treatment of crystals 
 
2.10.1 Principles of protein crystallisation 
 
Like small molecules, proteins can form crystals in appropriate conditions. Proteins 
align themselves to form a three-dimensional lattice (Figure 2.3). The importance of 
crystals in structural studies of macromolecules is that they can be used to determine 
three-dimensional structures by X-ray diffraction.  
  
Figure 2.3 Three-dimensional lattice of protein crystal.  
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Crystallisation is a phase transition phenomenon, and there are two principal regions in 
a crystallisation phase diagram (Figure 2.4): supersaturated and undersaturated regions. 
The supersaturated region includes a precipitation zone, a nucleation zone (labile zone) 
and a metastable zone. Crystals grow in the supersaturated region, and dissolve in the 
undersaturated region (Asherie, 2004). There are three stages, nucleation, crystal growth 
and cessation, in the crystallisation of all molecules. Both nucleation and growth of 
crystals occur in the supersaturated region, but require different concentrations of 
protein. Nucleation and growth compete at higher protein concentration (labile zone), 
and only growth occurs in the lower concentration of the metastable zone (Weber, 
1997). The strategy for crystallisation is to drive the system from the undersaturated to 
the saturated zone. Therefore, proteins are crystallised by changing factors that affect 




Figure 2.4 A schematic drawing of a protein crystallisation phase diagram based on 
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For the macromolecule Purity, stability, biochemical or genetic modification, 
etc 
Chemical factors pH, precipitant, ionic strength, specific ions, etc 
Physical factors Temperature, crystallisation method, time, etc 
Table 2.4 Factors affecting crystallisation. 
 
 
Many different approaches for crystallisation have been developed. Vapour diffusion is 
the most commonly used method for protein crystallography, altering the precipitant 
concentration. Mixed protein and precipitant solutions are either suspended over 
(hanging drop) or sitting in a well next to (sitting drop) a large reservoir of precipitant 




Figure 2.5 Hanging drop and sitting drop vapour diffusion methods. 
 
 
However, macromolecular crystal growth is still unpredictable, and some proteins 
apparently cannot be crystallised. There are two steps for obtaining crystals: crystal 
screening and crystal optimization.  
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2.10.2 Crystal screening 
 
Crystal screening uses a range of kits of prepared precipitant and additive compounds to 
obtain initial crystals. Concentrated protein (5-40 mg/ml) was used for setting up 
nanolitre crystallisation experiments using the sitting-drop vapour diffusion method. 
Typically, 70 µl of reservoir was transferred into subwell 1 of MRC-LMB plates from 
the crystallisation screening kits, and 100 nl of protein solution was mixed with 100 nl 
of reservoir using a Mosquito Liquid Handing robot (TTP Labtech). Then the plates 
were put into an 18°C incubator, and imaged every 3 days for 8 weeks using 
CrystalLIMS™ (TriTek), a laboratory informatics management system. 
 
2.10.3 Optimization of crystallisation conditions 
 
Crystals are usually not good enough to be used for X-ray data collection after crystal 
screening, and need to be optimized to obtain diffraction-quality crystals for structure 
solution. Both size and the order of a protein crystal are important. In the previous 
section, many factors that affect protein crystal growth were described. Crystal 
optimization involves systematically changing these conditions, such as chemical 




Crystallisation conditions are often not optimal for both nucleation and growth of 
crystals. Nucleation is more likely to occur in higher levels of protein concentration, 
whereas growth of crystals is favored by lower protein levels (see section 2.8.1, Figure 
2.4). Seeding is an important method to optimize crystallisation conditions by 
separating nucleation and growth of crystals (Bergfors, 2003). Macroseeding and 
microseeding are two methods classified by the size of the seeds. Macroseeding is a 
powerful technique to enlarge the size of crystal but requires much more labour for 
washing crystals repeatedly and carefully. Thus, microseeding is often tried first before 
macroseeding for crystal optimization. It can induce rapid crystal formation and 
improve the size of the crystal during the crystallisation process of certain proteins. 
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There are several methods of microseeding in terms of handling of micro-seeds. In this 
thesis, commercial seed beads from Hampton Research and cat whiskers were used for 
seeding. Normal crystallisation trials were set up and a cat-whisker was used to transfer 
seed crystals to new drops by streaking the whisker through the drop.  
 
2.10.5 Soaking and co-crystallisation 
 
After crystallisation of a protein, soaking may be used to obtain protein-ligand 
complexes or heavy-atom derivatives (Beck et al., 2009; Hassell et al., 2007; Kim and 
Haren, 1995). Co-crystallisation is an alternative method, and may also optimize 
crystallisation conditions and produce larger and/or more ordered crystals. 
 
Soaking crystals is convenient and reproducible, but several factors need to be 
considered, such as the soaking time, ligand solubility and concentration. (Hassell et al., 
2007). The soaking times may range from several minutes to several months for 
different protein-ligand complexes. A gradient soak with stepwise increase in ligand 
concentration or different solvent can be a valuable option. The disadvantages are that 
crystal packing may inhibit a ligand’s access to binding sites, or the ligand may cause 
structural changes that destroy the crystal. 
 
Co-crystallisation is a method to mix the ligand and the protein to form a complex that 
is subsequently used for crystallisation. During crystal growth, the ligand is 
incorporated into the crystal lattice. However, the presence of the ligand in the 
crystallisation drop may cause unpredicted influences on the crystallisation process.  
 
Soaking and co-crystallisation methods were used to obtain calcium-bound derCD23 




X-ray data collection of cryo-cooled crystals is an essential technique for structure 
determination of macromolecules (Garman, 1999; Garman and Schneider, 1997; Hope, 
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1990). The crystals need to be in a solution that contains cryo-protectant to suppress ice 
formation in the ultra-low temperature. Glycerol, MPD and low molecular weight PEGs 
are often used as cryo-protectants. Salts, sugars, paratone, alcohols and other agents are 
also good cryo-protectants for some proteins (Rubinson et al., 2000). Although 15-25% 
glycerol is suitable for most crystals, it does not mean that glycerol is the best cryo-
protectant. Testing with different cryo-protectants is necessary for data collection. 
Several methods to transfer crystals into cryo-protectant have been developed: dialysis, 
co-crystallisation, rapid transfer etc. (Fernandez et al., 2000; Sousa, 1995). Cryo-
protectant was added to calcium-bound derCD23 crystals by co-crystallisation, whereas 




One of the major differences between protein and salt crystals is the high solvent 
content of protein crystals. 25-85% by volume of the protein crystal consists of 
channels, which are mostly occupied by water molecules. These water molecules play 
an important role in maintaining the structure of protein molecules in the crystal (Frey, 
1994). However, high solvent content may be associated with loose packing of protein 
molecules, and reduction of the solvent content of crystals may produce more ordered 
crystals, extending the resolution of crystal diffraction (Salunke et al., 1985). 
Dehydration is a post-crystallisation method to improve diffraction of protein crystals 
by reducing solvent content.  
 
Several dehydration protocols have been developed (Heras and Martin, 2005). One 
method is to allow crystals in a capillary tube to lose water to the atmosphere or to 
different saturated salt solutions. Crystal dehydration can also be achieved by 
transferring the crystals to a dehydrating solution with a higher concentration of 
precipitant. A gentle dehydrating method is to change the reservoir into a more 
dehydrating solution. Dehydrating methods were used to attempt to improve the 
diffraction resolution of derCD23/Fcε3-4 crystals, although no improvement was 
observed. 
 




Cryo-cooled crystals are used for data collection since it reduces radiation damage and 
increases lifetime. Flash-cooling of crystals is essential in order to produce an 
amorphous form of water that avoids ice formation and damage to the crystal (Heras 
and Martin, 2005; Kriminski et al., 2002). Nevertheless, flash-cooling of crystals may 
cause lattice disorder, increased mosaicity and reduced diffraction resolution (Heras and 
Martin, 2005). Mosaicity is a measure of the long-range disorder of a crystal. Lower 
mosaicity indicates more ordered crystals. 
 
Annealing is a method to reduce mosaic spread by warming the crystal to room 
temperature and flash-cooling it again. There are three different protocols: 
macromolecular crystal annealing (MCA), flash-annealing (FA) and annealing on the 
loop (AL) (Heras and Martin, 2005). MCA consists of moving the crystal from the cold 
gas stream to cryoprotectant for about 3 minutes and flash-cooling again (Harp et al., 
1998). FA and AL are annealing methods that involve blocking the cold gas stream 
(Yeh and Hol, 1998). Annealing methods were used to attempt to improve the 
diffraction resolution of derCD23/Fcε3-4 crystals, but no improvement was observed. 
 
2.11 Data collection and processing 
 
2.11.1 Data collection 
 
X-ray data collection involves many choices, which influence the quality of the final 
data. The X-ray source should match the properties of crystal (Nave, 1999). Bigger, 
single crystals with low mosaicity and high order are preferred to collect high 
diffraction quality data (Evans, 1999). Strategies of data collection are important to 
obtain data with high redundancy and completeness by choosing the optimal exposure 
time, resolution range, overall rotation range and angular range per frame (Dauter, 
1999; Evans, 1999).  
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Cryo-crystallography was routinely used for data collection for all crystals studied and 
reported in this thesis. Crystals were mounted with a nylon loop and frozen in liquid 
nitrogen before taking to the Diamond Light Source (Synchrotron) for data collection 
(Pflugrath, 2004). A temperature of 100 K was maintained under a nitrogen stream to 
minimise radiation damage to the crystals (Garman, 2010).  
 
All datasets were collected from single crystals at the Diamond Synchrotron. Initial 
diffraction images were inspected with MOSFLM (Battye et al., 2011) to determine 
space group and unit cell parameters by the autoindexing function. Space group and unit 
cell parameters were identified according to the penalty and symmetry of space group 
from the list provided by MOSFLM. If all observed reflections overlay with MOSFLM 
placing boxes for predicted spots according to the selected space group and cell 
dimensions, then these unit cell parameters are correct. Then the Strategy program was 
used to calculate the starting angle and minimum oscillation (ϕ) range for collecting a 
complete dataset.  
 
2.11.2 Data processing 
 
Initially, HKL2000 was used for data processing after data collection. The HKL2000 
program package contains three parts: XdisplayF for visualization, Denzo for data 
reduction and integration and Scalepack for merging and scaling (Otwinowski and 
Minor, 1997). Some datasets were processed by a combination of MOSFLM and 
SCALA (Evans, 2006), if they failed with HKL2000.  
 
Several statistical parameters were used to assess the quality of the collected data:  
I/σ (I), Redundancy, Rmerge (or Rpim) and Completeness.  
 
I/σ(I): ratio between the average intensity of the reflections and their corresponding 
standard deviation. 
Redundancy: ratio between the number of measured and independent reflections. 
Rmerge = ΣreflΣi|Ii- Iaver|/ΣreflΣiIi , where Ii is the intensity of a ith measurement of a 
reflection Iaver the average intensity for that reflection, calculated on all the 
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measurements acquired for that reflection. Σrefl indicates the sum calculated over all the 
independent reflections measured.  
Rpim= Σrefl(1/(nrefl -1))Σi|Ii - Iaver|/ΣreflΣiIi , where nrefl is the number of observations of a 
reflection. Rmerge is not a good measure of data quality, as it tends to increase with 
increasing redundancy. Redundancy-independent Rpim is better to assess data quality 
when redundancy is high (Evans, 2006). 
Completeness: ratio between the number of crystallographic reflections measured in a 
dataset and the total number of reflections present at the specified resolution.  
 
2.12 Matthews coefficient calculation 
 
Matthews coefficient (Vm) is calculated using the formula: Vm = V/(n×M) (Matthews, 
1968). Vm is usually found to have values between 1.6 and 3.5 Å3Da-1depending on the 
solvent content of the crystals. Thus, this is a way to estimate the number of molecules 
in the asymmetric unit. 
V = volume of the unit cell 
n = the number of asymmetric units in the unit cell 
M = molecular weight of the contents of the asymmetric unit 
Asymmetric unit: the smallest unit that can be rotated and translated by the symmetry 
operators of the crystallographic space group. It can contain part of a molecule or 
several molecules.  
 
2.13 Structure solution, model building and refinement 
 
2.13.1 Molecular replacement 
 
In order to calculate the electron density map from the X-ray diffraction pattern, both 
the structure factor amplitudes and the phase are required. The structure factor 
amplitudes are obtained from the intensities of the reflections, whereas the phase 
information is lost during data collection. The lost phase information can be obtained by 
several different approaches. Molecular replacement is now the most used method 
according to the record in the Protein Data Bank (PDB) (Evans and McCoy, 2008).  
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Molecular replacement derives phase information from a known structural model, 
which is partially the same as the target structure. Molecular replacement is a six-
dimensional movement: 
 
x’ = Rx + T 
 
The coordinates of the structure to be solved (x’) are a transformation of the input model 
(x). Three parameters define a rotation matrix (R), and three parameters define the 
translation vector (T). In this thesis, all structures were solved by molecular 
replacement, performed by PHASER, which is developed using maximum likelihood 
method (McCoy et al., 2007). An input model can be rotated and translated to create 
numerous hypotheses of orientation and position of the model in the unit cell. All 
hypotheses are tested by measuring the consistency of the model with the data. A high 
probability that the data could be observed indicates a better solution. 
 
2.13.2 Model building and refinement 
 
If the calculated phases are good, then a model can be built into the resulting electron 
density. Model building of all structures was performed by COOT (Emsley et al., 
2010), a program that is particularly suitable for protein modeling using X-ray data. 
2Fo-Fc (typically 1σ level) and Fo-Fc (typically 3σ level) electron density maps were 
calculated and used for manual building. Loop 4 and loop 1 of derCD23 were deleted at 
the beginning, and built gradually into the structure according to the positive difference 
map. 
 
After manual model building, the coordinates and temperature factors were refined 
against the observed X-ray data in REFMAC (Murshudov et al., 2011) or PHENIX 
(Adams et al., 2011) to minimize the differences between the experimental structure 
factor amplitudes and those from the model calculation. In this thesis, rigid body 
refinement in REFMAC was used after molecular replacement to move the overall 
molecules as a unit at lower resolution (10-4 Å). Then TLS and restrained refinement 
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was carried out using REFMAC or PHENIX. These two programs also contain 
restraints to maintain correct stereochemistry, such as NCS, bond lengths and angles. 
The weighting between the observed X-ray data and the stereochemistry of the model 
was adjusted to obtain the lowest Rwork, Rfree and best stereochemistry. R.m.s. deviations 
in bond lengths and angles, Rwork and Rfree were used to monitor the progress of the 
refinement. Fitting of structure to the electron density maps and temperature factor 
values were also considered to assess the progress of refinement. 
 
For the refinement of low resolution structure, local NCS restraints, “jelly-body” 
restraints and map sharpening were used in REFMAC (Murshudov et al., 2011).  
 
Definitions: 
2Fo-Fc map: represents the density corresponding to the structure. 
Fo-Fc map: represents differences between the real structure and the current model. 
Temperature factor (B-factor): also known as atomic displacement parameter (ADP), a 
measure of how much an atom vibrates around its mean position. 
TLS refinement: a method to include anisotropic displacement refinement of a set of 
selected atoms as a rigid body requiring only 20 parameters at medium to low 
resolution. TLS represents translation (6 parameters), libration (6 parameters) and 
screw-motion (8 parameters). 
NCS restraints: Non-crystallographic symmetry (NCS) restraints can be used when 
there are two or more copies of a protein molecular in the asymmetric unit. Atoms are 
restrained to their NCS related equivalents during refinement.  
Local NCS used in REFMAC: if interatomic distances less than a set number in atom 
pairs, and the distances are similar in NCS related equivalents, then these atom pairs are 
included in NCS restraints (Murshudov et al., 2011). 
“Jelly-body”: a method to control interatomic distances for pairs of atoms from the 
same chain during refinement.  
Map sharpening: a method attempt to increase signal while reducing amplification of 
noise. 
Rwork = Σ||Fobs| - |Fcalc||/Σ|Fobs|, where Fobs and Fcalc are the observed and calculated 
structure factor amplitudes. 
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Rfree = Σt||Fobs| - |Fcalc||/Σt|Fobs|, where Fobs and Fcalc are the observed and calculated 
structure factor amplitudes, and t is the test set of data omitted from refinement (5% in 
this case). 
R.m.s. deviations (root-mean-square deviations) in bond lengths and angles: a measure 
of how well the structure model conforms to the ideal values of bond lengths and bond 
angles in crystallography.  
 
2.14 Structure validation 
 
The final model was analyzed with the software Molprobity to check its quality, such as 
protein geometry and all-atom contacts (Chen et al., 2010). The bond torsion angles of 
the polypeptide backbone of proteins adopt preferred combinations (Ramakrishnan and 
Ramachandran, 1965). Molprobity analyses the model by comparing the model with 
these preferred conformations. A Ramachandran plot can be obtained to show the 
deviations (Ramachandran et al., 1963).  
 
2.15 Figure preparation 
 
Images of all structures and electron density maps were produced using PyMOL 
(http://www.pymol.org).  
 
2.16 Structural analysis 
The interaction between derCD23 and Fcε3-4, and the buried surface area are calculated 
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Chapter 3: 




C-type lectins are a large group of Ca2+-dependent (C-type) carbohydrate-binding 
(lectin) proteins. However, some proteins in the C-type lectin-like domain (CTLD) 
superfamily fold like a lectin, but require neither calcium nor carbohydrate for their 
function (Drickamer, 1999; Zelensky and Gready, 2005). A large number of structures 
of CTLDs in the Protein Data Bank (PDB) provide a detailed understanding of the 
topology and Ca2+-binding sites of this family of proteins. Four Ca2+-binding sites have 
been identified in CTLDs depending on the CTLD sequences and the crystallisation 
conditions (Figure 3.1) (Zelensky and Gready, 2005). In the rat mannose binding 
protein-A, Ca2+-binding site 3 is considered as a crystallographic artefact according to 
biochemical data (Loeb and Drickamer, 1988; Weis et al., 1992). In most CTLDs, Ca2+-
binding site 2 is involved in carbohydrate binding. 
 
Figure 3.1 Ca2+-binding sites in CTLDs. 
Shown are ribbon diagrams of two representative CTLD structures, human asialoglycoprotin 
receptor-I (ASGPR-I) and rat mannose binding protein-A (MBP-A), demonstrating the four 
typical locations of calcium ions in the CTLDs (Figure taken from Zelensky et al., 2005).  
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According to the sequence alignment of Ca2+ site ligands in various species of CD23 
and other C-type lectins, there are two putative Ca2+-binding sites in human CD23 
(Figure 3.2). E257 belongs to both calcium binding “site 1” and “site 2”. “Site 1” is not 
well conserved, as N225 and K229 are not classical Ca2+-binding residues. The NMR 
structure of derCD23 was determined, and NMR titration experiments indicated Ca2+ 
binding to “site 1” (Hibbert et al., 2005). Then the crystal structure of the CTLD of 
CD23 double mutant (H213R and G256S) was reported and Ca2+ was observed in “site 
2” (Figure 3.3A) (Wurzburg et al., 2006). This CD23 construct contained two mutations 
that were not apparently included for any functional reason. No explanation was 
provided in the paper. The two methods therefore gave conflicting results concerning 
the location of Ca2+ (Figure 3.4). In addition, loop 4 (residues 253-257) is disordered in 
the Ca2+-bound structure of CD23 double mutant (Figure 3.3B). This is inconsistent 
with the suggested role of Ca2+ in stabilizing the carbohydrate binding conformation of 
the loop in MBP (Ng et al., 1998; Sun, 2006).  
 
 
Figure 3.2 Calcium site ligands of CD23 in various species. 
An alignment of CD23 sequences from rat, house mouse, horse, cow (partial), and human 
sources showing the calcium-ligating residues. For comparison, the corresponding residues 
from the human asialoglycoprotein receptor (HL), rat MBP-A, and human DC-SIGN are shown 
above the CD23 sequences. Ca2+ “site 1” ligands are highlighted in green, the conserved proline 
is highlighted in blue, Ca2+ “site 2” ligands are highlighted in pink. Non-conservative 
substitutions in the human sequence are highlighted in yellow. The E257 acts as both a “site 1” 
(side chain O3) and “site 2” (main chain O) ligand. The human CD23 numbering is given below 
the sequences (Figure adapted from Wurzburg et al., 2006). 
 




Figure 3.3 Structure of the calcium-bound CD23 double mutant. 
A: The calcium binding site. The calcium is shown as a green sphere, and its ligands come from 
four residues E249, T251, N269, D270 and two waters. B: Superimposition of calcium-bound 
and calcium-free CD23 double mutant structures (PDB code 2H2T and 2H2R). The calcium-
bound form is shown in red, and the calcium-free form is shown in blue. Loop 4 is disordered in 





Chapter 3  The crystal structure of Ca2+-bound derCD23 	  
 64 
  
Figure 3.4 Structures of CD23 head domain. 
NMR structure (PDB code 1T8D) and the Ca2+ ion (“site 1”) observed in the NMR titration 
experiment are indicated in blue (Hibbert et al., 2005). Crystal structure of CD23 double mutant 
(PDB code 2H2T) and the Ca2+ ion (“site 2”) observed are indicated in red (Wurzburg et al., 
2006). The IgE binding site mapped by NMR (Hibbert et al., 2005) is close to the calcium 
binding sites on CD23. (Figure adapted from Gould and Sutton, 2008) 
 
Thus, the crystal structure of Ca2+-bound derCD23 was determined in order to resolve 
previous controversy concerning the calcium binding site(s). Comparison of derCD23 
structures will provide details of Ca2+-dependent structural changes in human CD23. 
 
3.2 Cloning, refolding, expression and purification of derCD23 and derCD23 
mutants 
 
3.2.1 Cloning and expression of derCD23 
 
The E.coli strain BL21(DE3) containing pET5a-derCD23 vector was obtained from 
Prof. James McDonnell. The pET5a vectors containing derCD23 mutants (E249A, 
S252A, D258A, D270A) were provided by Dr. Balvinder Dhaliwal. Site directed 
IgE	  binding	  region	  
mapped	  by	  NMR 
site	  2 
Site	  1 
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mutagenesis of derCD23 to produce the mutants N269A and N269D was carried out 
using QuickChange kit (Stratagene, CA, USA) (Section 2.2.2).  
 
DerCD23 and derCD23 mutants were expressed as insoluble inclusion bodies (Figure 
3.5). If the concentration of cell culture was too high (OD600>0.8) or the induction time 
was too long (more than 8 hours), yields of proteins were found to be reduced.  
 
 
Figure 3.5 15% reducing SDS-PAGE of derCD23.  
Lane 1: before induction; Lane 2: after induction; Lane 3: inclusion body; Lane 4: fractions of 
the peak in heparin column profile (Figure 3.6); Lane 5: heparin column flowthrough; Lane 6-7: 




3.2.2 Refolding  
 
The protocol from Professor McDonnell’s lab was previously optimized (Hibbert et al., 
2005). However, small changes were made in order to make well-refolded proteins 
every time (Section 2.4). Washing of inclusion bodies with 20 mM Tris pH 7.5 was 
prolonged to 16 hours, and protein samples were diluted into refolding buffer as slowly 
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as possible, normally 4 hours for 150 ml protein samples. Protein samples may form 




The heparin column and size-exclusion column were mainly used to separate folded and 
unfolded proteins. The purification profile of derCD23 by heparin column showed a 
large peak, which indicates that there are derCD23 proteins binding to the column 
(Figure 3.6). Then, fractions of the peak were collected and loaded onto the size-
exclusion column. At the beginning, NMR buffer (10 mM Tris pH 6.8, 125 mM NaCl, 4 
mM calcium chloride) was used for running the size-exclusion column, but there was a 
lot of precipitation and this caused the column to become jammed. Then 20 mM Tris 
pH 7.5 was used for the gel filtration buffer. This modification produced two peaks 
(Figure 3.7). The first peak contained aggregated protein, and the second peak contained 
well-folded monomeric protein. 10 mg protein was typically obtained from 1 litre of 




Figure 3.6 Purification profile of derCD23 by heparin column.  
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Figure 3.7 Purification profile of derCD23 on a Superdex 200 column. 
The first peak contains unfolded, aggregated protein, and the second peak consists of well-
folded monomeric protein. 
 
 
3.2.4 1D NMR spectroscopy 
 
After purification using the size-exclusion column, the second peak was collected and 
used for 1D-1H NMR. Protein samples were dialyzed into 10 mM Tris pH 6.8, 125 mM 
NaCl, 4 mM calcium chloride and 5% D2O. The concentration of derCD23 and mutants 
were adjusted to about 1mg/ml and the volume was about 0.5 ml. The large dispersion 
and strong signals of methyl groups between 1.0 and -1.0 ppm indicated that derCD23 
and all four of the derCD23 mutants (E249A, D270A, S252A and D258A (not shown)) 
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Figure 3.8 1D-1H NMR spectra of derCD23 and derCD23 mutants. 
The large dispersion and strong signals of methyl groups between 1.0 and -1.0 ppm indicated 
that the proteins were well-refolded. The 1D-1H NMR spectrum of mutant D258A looked 
identical to those shown here. 
 
 
3.3 Crystallisation of wild-type Ca2+-bound derCD23 
 
3.3.1 Crystallisation of wild-type derCD23 
 
There were two crystallisation conditions previously identified for CD23 head domain. 
The experimental conditions used by Dr. Stella Fabiane (unpublished data) were as 
follows: protein (3.5 mg/ml in 25 mM Tris pH 7.5, 137 mM NaCl, 2 mM CaCl2) was 
mixed 1:1 with precipitant (18.5% PEG 5000 MME or other PEG, 2% 1,6-hexanediol, 
0.05 M ammonium sulphate, 0.1 M sodium acetate pH 4.7). The experimental 
conditions given in Wurzburg et al (2006) were: protein (10 mg/ml in 30 mM Tris pH 
8.0, 10 mM CaCl2) was mixed 1:1 with precipitant (17% w/v polyethylene glycol 4000, 
100 mM MES buffer pH 6.0). Crystals of wild-type derCD23 were only obtained in the 
optimised first condition (18.5% PEG 6000, 2% 1,6-hexanediol, 0.05 M ammonium 
sulphate, 0.1 M sodium acetate pH 4.7) and used for calcium soaking (Figure 3.9).  
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3.3.2 Calcium soaking into wild-type derCD23 crystals 
 
In initial experiments, the derCD23 crystals were soaked with 10 mM CaCl2. However, 
no calcium was found to be bound to derCD23 after determining the structure (data not 
shown). Consideration of the crystallisation conditions suggests two possible reasons 
why there was no calcium binding. The first possible reason is the low pH value (4.7) of 
the crystallisation conditions that may prevent certain residues of derCD23 binding to 
calcium, such as E249 and D270. The second possible reason is that ammonium 
sulphate and CaCl2 can form poorly soluble calcium sulphate, which leads to 
precipitation in the crystallisation condition and loss of calcium. Thus, crystals of wild-
type derCD23 were soaked after increasing the pH to 7.1, removing the ammonium 
sulphate, adding 10 mM CaCl2 and increasing the concentration of precipitant in the 
original crystallisation condition (25% PEG 6000, 2% 1,6-hexanediol, 0.1M MES pH 
7.1, 10 mM CaCl2, 15% glycerol). 
 
 
Figure 3.9 Crystals of wild-type derCD23. 
Crystals grown in 18.5% PEG 6000, 2% 1,6-hexanediol, 0.05 M ammonium sulphate, 0.1 M 
sodium acetate pH 4.7. The longest dimension of the biggest crystal is 100 µm.  
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3.4 Data collection and processing 
 
3.4.1 Data collection and processing 
 
All datasets were collected from single wild-type derCD23 crystals, separated from 
clusters of crystals, at the Diamond Synchrotron using a q315 CCD detector and 
radiation of wavelength λ= 0.9763 Å. The dataset of calcium-bound derCD23 giving 
the highest resolution diffraction was used, and a summary of collection and processing 
of the derCD23 data is shown in Table 3.1.  
 
 
Space group P1 
Unit-cell parameters (Å, degrees) a = 54.24 α = 112.92 
b = 53.71 β = 88.53 
c = 56.64 γ = 114.96 
Wavelength (Å) 0.9763 
Resolution range (highest shell) (Å) 50.0-2.00 (2.07-2.00) 
Number of unique reflections 34591 
Redundancy 4.0 
Completeness (%) 97.9 (96.9) 
I/σ (I) 20.5 (4.6) 
Rmerge (%) 9.6 (40.6) 
Table 3.1 Data collection and refinement statistics of wild-type derCD23 (Ca2+soak). 
Values in parentheses are for the highest resolution shell. 
Rmerge = ΣreflΣi|Ii- Iaver|/ΣreflΣiIi , where Ii is the intensity of a ith measurement of a reflection Iaver 
the average intensity for that reflection, calculated on all the measurements acquired for that 
reflection. Σrefl indicates the sum calculated over all the independent reflections measured.  
 
 
3.4.2 Determination of space group and number of molecules in the asymmetric 
unit 
 
The space group (P1) is the same, but cell parameters (a = 54.24 Å, b = 53.71 Å, c = 
56.64 Å, α = 112.92°, β = 88.53°, γ = 114.96°) are different from the previously solved 
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calcium-free derCD23 structure (Dr. Stella Fabiane, unpublished data). The Matthews 
coefficient calculation indicated the presence of four derCD23 molecules per 
asymmetric unit (Matthews coefficient 2.11 Å3Da-1, 41.6% solvent). 
 
3.5 Structure solution and refinement 
 
3.5.1 Molecular replacement solution 
 
The structure of calcium-bound derCD23 was solved by molecular replacement using 
PHASER with the structure of human CD23 double mutant (PDB code 2H2R, 
Wurzburg et al, 2006) as the search model. As described above, this CD23 construct 
contained two mutations that were not apparently included for any functional reason. In 
order not to bias the electron density map calculations, water molecules were removed 
from the search model.  
 
3.5.2 Model building and refinement 
 
Manual model building was carried out with COOT, coupled with refinement using 
REFMAC5 and PHENIX. The progression of the refinement was monitored using R 
factors (Rwork and Rfree), and TLS refinement (Painter and Merritt, 2006) was 
implemented by finding TLS groups (four groups for chains B and C, twelve groups for 
chains A and D) in PHENIX. NCS restraints were used to all chains (residues 160-224, 
232-252, 258-288), and individual B-factor refinement was applied. Protein atoms of 
the backbone were modeled first. Disulphide bonds C163-C174 in all four chains, and 
C259-C273 in chains A and B were partially broken. The explanation for this may be 
radiation damage during data collection. They were refined for both intact and broken 
conformations with 0.5 occupancy for each. Water and glycerol molecules were 
modeled according to electron density at a later stage using the Rfree as a guide. The 
length of potential hydrogen bonds and the B-factor were considered when water and 
glycerol molecules were checked. 404 water molecules and 3 glycerol molecules were 
accepted.  
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In the final stage, four calcium atoms were modeled, one into each molecule in the 
asymmetric unit. Because water and calcium have similar electron density, both were 
tested in refinement. A comparison of their Fo-Fc maps and B-factor was used to 
determine whether calcium should be built into the structure. When a calcium ion was 
built into each chain, the 2Fo-Fc map fitted well with calcium, and there was no 
obvious difference density around it. B-factor for the four calcium ions in chains A, B, 
C and D are 32, 22, 35 and 53 respectively. When water was built into the density for 
calcium, it showed an unusually low B-factor and was surrounded with positive Fo-Fc 




Figure 3.10 Electron density maps in the region of the calcium binding site in Chain B.  
A: Calcium was modeled into calcium “site 2”, and the B-factor for this calcium is 22. 2Fo-Fc 
map (purple) fitted well with calcium while no obvious difference density surround it. The 
green map is positive difference density, and there is no visible red negative difference density. 
B: Water was modeled into calcium “site 2”, and the B-factor for this water is zero. The water is 
surrounded by positive difference density (green). 
2Fo-Fc (1σ level) electron density maps are shown in purple or blue, and Fo-Fc (3σ level) 
electron density maps are shown in red (negative but not visible) and green (positive). The 
location of calcium and water are shown as white and pink crosses respectively, and the strong 
Fo-Fc positive density in B surrounding the placed water molecule is clearly seen. 
 
 
The derCD23 (residues 156-298) head domain was well modeled, while N- and C-
terminal regions were missing in the structure. The structure contains residues 159-290 
for chain A, 157-291 for chain B, 160-289 for chain C and 160-288 for chain D. The 
calcium binding ligands (residues E249, T251, D270 and three waters) are clearly 
A B 
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observed in three chains (A, B and C), but electron density for the three waters and 
T251 is poor in chain D. The final refinement statistics are presented in Table 3.2. 
 
 
Number of:  
Protein atoms 4271 
Water molecules 404 
Calcium ions 4 
Glycerol molecules 3 
Average B factors (Å2):  
Protein 25.7 
Water molecules 35.0 
Calcium ions 35.8 
Glycerol molecules 46.0 
Protein (chain A) 25.9 
Protein (chain B) 23.7 
Protein (chain C) 26.1 
Protein (chain D) 27.2 
Rwork/Rfree(%) 15.2/20.5 
r.m.s. deviations bond lengths = 0.006 Å 
bond angles = 0.963° 
Table 3.2 Statistics of the refinement process for the calcium-bound derCD23 structure. 
Rwork = Σ||Fobs| - |Fcalc||/Σ|Fobs|, where Fobs and Fcalc are the observed and calculated structure 
factor amplitudes. 
Rfree = Σt||Fobs| - |Fcalc||/Σt|Fobs|, where Fobs and Fcalc are the observed and calculated structure 





The refined structure was analysed with Molprobity as indicated in section 2.9.5. An 
analysis of the corresponding Ramachandran plot (Figure 3.11) showed that all the 
residues are in allowed regions. 
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Figure 3.11 Ramachandran plots for the calcium-bound derCD23 structure, calculated 
with the Molprobity server. 
From the top left: plot of φ and ψ angles for the general case, glycine, proline and pre-proline 
residues. All the residues, indicated by small black circles, were in allowed (dark blue) regions. 
96.2% of residues were in the favoured (light blue) regions. 
 
3.6 Overall structure of CD23 
 
There are four molecules in the asymmetric unit of this derCD23 crystal form. 
Superimposition of all 4 copies reveals similar arrangement of the head domain and 
only slight variations in loop 1, but more differences in loop 4. Calcium is bound to 
each of the derCD23 molecules (Figure 3.12). The 2.0 Å Ca2+-bound derCD23 structure 
has the topology of a C-type lectin domain. The structure consists of two α helices and 
Chapter 3  The crystal structure of Ca2+-bound derCD23 	  
 75 
two β sheets formed by eight β strands. Four disulphide bonds (C160-C288, C163-
C174, C191-C282 and C259-C273) contribute to the tertiary structure. The partial 
cleavage of some disulphide bonds is probably the result of radiation damage during 
data collection (Section 3.5.2). Unlike previously solved CD23 crystal structures (PDB 
code 2H2R and 2H2T, Wurzburg et al, 2006), electron density of all the head domain is 
well observed, including loop 1 (226-231) and loop 4 (253-257) that contribute to IgE 
binding.   
 
 
Figure 3.12 Cartoon representation of the derCD23 structure showing all four molecules. 
Loop 1 and loop 4 are shown as red and magenta respectively. Four disulphide bonds (C160-
C288, C163-C174, C191-C282 and C259-C273), indicated in yellow, contribute to the tertiary 
structure. The four calcium ions are shown as grey spheres. 
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3.7 Calcium binding site in derCD23 
 
In the asymmetric unit, there are four derCD23 molecules with one calcium bound to 
each of them. Unlike MBP and DC-SIGN, human CD23 contains only calcium bound at 
“site 2”. Electron density for the calcium binding ligands (residues E249, T251, D270 
and three waters) and the Ca2+ ion is clearly observed in three derCD23 molecules 
(Section 3.5.2). The electron density of the fourth calcium in chain D is poor. This is not 
apparently the result of crystal packing differences.  
 
The coordination of calcium is different from that seen in the previously solved 
structure of the CD23 double mutant (Figure 3.3A, Wurzburg et al, 2006). This 
difference with the derCD23 double mutant structure will be described later (Section 
3.9). There are only 3 residues (E249, T251 and D270) providing 4 oxygen atoms and 3 
water molecules providing 3 oxygen atoms involved in the binding to Ca2+ in 3 of 4 
molecules in the asymmetric unit (Figure 3.13). The distances between calcium and the 
ligands in these three chains (A, B and C) are shown in table 3.3. The geometry of the 
calcium coordination in site 2 is pentagonal bipyramidal formed by these seven ligands. 
This is different from the pentagonal bipyramidal with one bisected apex, formed by 
eight ligands, in site 2 of MBP, DC-SIGN and human asialoglycoprotin receptor-I 
(ASGPR-I) (Meier et al., 2000; Snyder et al., 2005; Weis et al., 1992; Wurzburg et al., 
2006). The bisected apex consists of two water molecules in these three carbohydrate-
free C-type lectins, while two carbohydrate oxygen atoms occupied this bisected apex in 
these carbohydrate-bound lectins.  In the fourth derCD23 molecule (chain D), site 
ligand T251 is far from Ca2+, and electron density for the water molecules is not clear.  
 
According to the alignment of CD23 sequences from various species (Figure 3.2), N269 
is expected to be a calcium ligand as it binds calcium in MBP, DC-SIGN and human 
asialoglycoprotin receptor-I structures, and is seen as such in the CD23 double mutant 
structure (Wurzburg et al., 2006). Surprisingly, N269 is not involved in the binding to 
Ca2+ in this derCD23 structure. In addition, E257, a residue expected to belong to both 
“site 1” and “site 2” on the basis of function as a calcium ligand in other CTLDs, is not 
a calcium ligand. 





Figure 3.13 Calcium binding to derCD23 as seen in 3 of 4 molecules in the asymmetric 
unit (chains A, B and C). 
Calcium binds to “site 2”, with 3 residues (E249, T251 and D270) providing 4 oxygen atoms 
and 3 water molecules providing 3 oxygen atoms involved in the binding of Ca2+. N269 is not 
involved. Potential “site 1” residues (S252 and D258) are distant from each other. 
 
 Chain A Chain B Chain C 
E249 OE1 2.68 2.65 2.75 
E249 OE2 2.54 2.58 2.66 
T251 OG1 2.62 2.44 2.71 
D270 OD1 2.61 2.44 2.59 
Water 1 2.59 2.56 2.93 
Water 2 2.70 2.62 2.66 
Water 3 2.42 2.43 2.89 
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3.8 Comparison with Ca2+-free derCD23 structure 
 
3.8.1 Difference between Ca2+-bound and Ca2+-free derCD23 structures 
 
Comparison of the calcium-bound derCD23 structure with the Ca2+-free derCD23 
structure solved by Dr. Stella Fabiane (unpublished, Table 3.4) reveals residues 
undergoing a conformational change upon calcium binding (Figure 3.14). Overall, the 
structures of derCD23 with and without calcium show little differences in secondary 
structure or packing of the core. However, there are large changes in loop 4 and small 
variations in loop 1. The four copies of loop 4 in the Ca2+-bound derCD23 structures 
adopt similar conformations. The four copies of loop 4 in Ca2+-free derCD23 have two 
different conformations, neither of which is the same as the Ca2+-bound conformation. 
This indicates that calcium functions to stabilize loop 4.  
 
 
Space group P1 
Unit-cell parameters (Å, degrees) a = 52.40 α = 68.49 
b = 56.73 β = 88.16 
c = 62.10 γ = 73.40 
Resolution range (highest shell) (Å) 57.2-2.25 (2.37-2.25) 
Rwork/Rfree(%) 17.3/23.6 
R.m.s. deviations bond lengths = 0.017 Å 
bond angles = 1.944° 
Protein (chain A) residues 157-291 
Protein (chain B) residues 157-291 
Protein (chain C) residues 159-290 
Protein (chain D) residues 159-289 
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Figure 3.14 Comparison of Ca2+-bound and Ca2+-free derCD23 structures. 
Orange: Ca2+-bound derCD23 structures. Blue and cyan: Ca2+-free derCD23 structures (Dr. 
Stella Fabiane unpublished data). Most of the residues undergoing a conformational change 
upon calcium binding are also involved in the interaction with IgE (Chapter 5). 
 
 
3.8.2 Insight into Ca2+-dependent structural changes in derCD23 
 
Comparison of the Ca2+-bound structure and these two different conformations of loop 
4 in the Ca2+-free structure reveal structural changes upon calcium binding. The two 
different conformations of Ca2+-free derCD23 represent independent views of derCD23 
in similar packing environments, and are not the result of different crystal packing 
interactions. In the Ca2+-free structure conformation 1, two calcium binding residues 
(E249 and D270) remain in a similar position as in the Ca2+-bound structure, whereas 
structural changes of the T251 side chain are observed. Only E249 remains in a similar 
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position in the Ca2+-bound structure as in the Ca2+-free structure conformation 2, while 
both T251 and D270 show structural differences. Residues 249-251 (EPT) show distinct 
differences between the Ca2+-bound and -free derCD23 structures due to the movement 
of P250 and T251. In the Ca2+-bound structure, the EPT motif is more bent and P250 
adopts a cis-conformation in all four copies in the asymmetric unit (Figure. 3.15). The 
distance between T251 (Oγ1) and E249 (Oε1) is 3.7 Å. In the Ca2+-free structure, the 
distance between T251 (Oγ1) and E249 (Oε1) is 6.1 Å in conformation 1 and 8.3 Å in 
conformation 2. In addition, P250 adopts a cis-conformation in conformation 1 and a 
trans-conformation in conformation 2. Thus, calcium binding causes movement of 
calcium site ligands and the trans to cis isomerization of P250. 
 
Unlike the Ca2+-bound structure, side chains of residues 253-254 in the Ca2+-free 
structure conformation 1 are disordered. Furthermore, the side chain of R253 in the 
Ca2+-free structure conformation 2 points into a cavity between loop 1 and loop 4 
(Figure 3.16). 
Chapter 3  The crystal structure of Ca2+-bound derCD23 	  
 81 
 
Figure 3.15 Comparison of the E249-P250-T251 conformations in derCD23 structures. 
A: Superimposition of EPT motif in Ca2+-bound derCD23 (orange) and two forms of Ca2+-free 
derCD23 structures (dark and light blue). P250 adopts a cis-conformation in the Ca2+-bound 
structure. P250 adopts a cis-conformation in conformation 1 and a trans-conformation in 
conformation 2 of the Ca2+-free derCD23 structure. B: EPT in the Ca2+-bound derCD23 
structure. C: EPT in the Ca2+-free derCD23 structure conformation 1. D: EPT in the Ca2+-free 
derCD23 structure conformation 2. 
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Figure 3.16 The conformation of R253 in derCD23 structures. 
A: Ca2+-bound derCD23 structure shows that R253 points away from the head domain. B: Ca2+-
free derCD23 structure in the conformation 2 has the R253 occupying the cavity between loop 1 
and loop 4.  
 
3.9 Comparison with previously solved CD23 structures 
 
The Ca2+-bound derCD23 structure showed a different Ca2+-binding site to the NMR 
structure, and different calcium coordination residues to the previous crystal structure of 
the CD23 double mutant. In addition, loop 4 is well ordered in the Ca2+-bound 
structures reported in this thesis, compared with the previous Ca2+-bound crystal 
structure of the CD23 double mutant, in which it is disordered.  
 
In the NMR titration experiment with calcium, observed chemical shifts of residues 
around Ca2+ “site 1”, not “site 2”, suggested the occupancy of Ca2+ in “site 1” (Hibbert 
et al., 2005). The comparison of Ca2+-bound and Ca2+-free derCD23 structures does 
indeed show differences in “site 1” residues, and little or no changes in most of the Ca2+ 
“site 2” residues. This may explain why the Ca2+ site was inferred to be “site 1” by the 
NMR titration experiment, although it is surprising that no shifts were observed at “site 
2”, caused by the presence of Ca2+ if not by structural changes in the ligands. In the 
previous crystal structure of Ca2+-bound CD23 double mutant, N269 is involved in 
Ca2+-binding, and loop 4 is disordered. A possible reason for the difference is that one 
of the mutations, G256S, is close to the Ca2+-binding site, and as part of loop 4, this 
mutation may cause the observed disorder of loop 4 and the changes in Ca2+ 
coordination. 
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3.10 Isothermal Titration Calorimetry 
 
ITC experiments with derCD23 and the four mutants (see chapter 4 for structural details 
and section 2.7 for experimental details) showed that wild-type derCD23 and mutant 
S252A indicate calcium binding, whereas mutants E249A, D258A and D270A showed 
no measurable calcium binding (Figure 3.17 and Table 3.5).  
 
Figure 3.17 Interactions between derCD23 (wild-type and mutants) and calcium studied 
with ITC. 
Black curve and squares:  wild-type derCD23.  Red squares: E249A. Green squares: S252A. 
Mutants D270A and D258A showed the same results as E249A. This experiment was 
performed by Dr. Anthony Keeble. 




 “Site 2” “Site 2” “Site 1” “Site 1” 

















* For definition of sites refer Figure 3.2. 
Table 3.5 Binding affinities of wild-type derCD23 and mutants for calcium studied by 
Isothermal Titration Calorimetry (ITC). 
Wild-type derCD23 and mutant S252A indicate calcium binding with a resulting KD = 1.5 mM, 
whereas mutants E249A, D258A and D270A showed no measurable calcium binding.  
 
 
After solving the calcium-bound derCD23 structure, N269 was found not to be involved 
in calcium binding, even though it belongs to “site 2” according to sequence alignment. 
Thus, two mutants N269A and N269D were made for ITC experiments to measure their 
binding affinity with calcium (see section 2.7 for experimental details). N269A and 
N269D were found to have binding affinities with a KD = 0.73 and 1.5 mM, respectively 
(Figure 3.18), consistent with N269 not being involved in calcium binding. 
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Figure 3.18 Interactions between derCD23 mutants (N269A, N269D) and calcium studied 
with ITC.  





3.11 Summary and discussion 
 
The low-affinity IgE receptor, CD23, plays a central role in the regulation of IgE 
synthesis and is involved in other IgE-dependent activities such as allergen presentation 
and transport. This membrane protein is different from other Ig receptors and belongs to 
the C-type lectin superfamily. According to the sequence alignment of Ca2+ site ligands 
in various species of CD23 and other C-type lectins, there are two putative Ca2+-binding 
sites in human CD23 (Figure 3.2). Monomeric derCD23, S156-E298 of the full-length 
CD23, is a recombinant protein corresponding to the fragment released by Der p I, 
which contains the lectin domain and part of the C-terminal tail. The NMR structure of 
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derCD23 had previously been determined, and NMR titration experiments indicated 
Ca2+-binding to “site 1” (Hibbert et al., 2005). Then the crystal structure of the CTLD 
of CD23 double mutant (H213R and G256S) was reported with and without Ca2+, and 
Ca2+ was observed to bind in “site 2” (Wurzburg et al., 2006).  
 
This chapter describes the purification, crystallisation and structure determination by X-
ray crystallography of the monomeric derCD23 CTLD. ITC experiments are also used 
to determine the calcium binding affinity and the binding site. Structural comparison of 
Ca2+-bound and -free structures reveals the effect of calcium on the structure of CD23 
head domain. 
 
The crystal structure of Ca2+-bound derCD23 was determined at 2.0 Å resolution, and 
resolves previous controversy concerning the Ca2+ binding site. The structure of 
derCD23 displays the typical tertiary structural arrangement of other CTLDs. There are 
four Ca2+-bound derCD23 molecules in the asymmetric unit of this crystal form. 
Superimposition of all 4 copies reveals similar arrangement of the head domain and 
only slight variations in loop 1, but more differences in loop 4. CD23 contains two 
potential calcium binding sites according to sequence alignment, but “site 1” is not well 
conserved in human CD23. This explains no calcium binding to site 1 in human CD23. 
The structure reported here shows that calcium binds to “site 2”, and has a different 
coordination compared with a previously solved CD23 (double mutant) structure. Three 
residues (E249, T251 and D270) provide 4 oxygen atoms and 3 water molecules 
provide 3 oxygen atoms involved in the binding to Ca2+. The geometry of the calcium 
coordination is pentagonal bipyramidal formed by seven ligands. The coordination is 
different from the pentagonal bipyramidal with one bisected apex, formed by eight 
ligands, in site 2 of MBP, DC-SIGN and human asialoglycoprotin receptor-I (ASGPR-
I) (Meier et al., 2000; Snyder et al., 2005; Weis et al., 1992; Wurzburg et al., 2006). 
This is probably the result of the fact that there is no carbohydrate binding to derCD23 
(Section 3.7). 
 
ITC experiments with derCD23 and the initial four mutants (see chapter 4 for structural 
details and section 2.7 for experimental details) were also used to determine calcium-
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binding site. Wild-type derCD23 and calcium-binding “site 1” mutant S252A indicate 
calcium binding with a KD = 1.5 mM, whereas “site 2” mutants E249A and D270A 
showed no measurable calcium binding (Figure 3.17 and Table 3.5). These results 
confirm that calcium binds to “site 2”. The structure of “site 1” mutant D258A explains 
the result of no measurable calcium binding of this mutant and will be described in 
chapter 4. The concentration of calcium in human serum is about 2 mM, which is 
around the binding affinity of derCD23 with calcium. This indicates that calcium-bound 
and -free derCD23 may be in a equilibrium that may have an important physiological 
role (see chapter 7).  
 
According to the alignment of CD23 sequences from various species, N269 is expected 
to be a calcium ligand and is seen as such in the derCD23 double mutant structure. 
Surprisingly, N269 is not involved in the binding to Ca2+ in the derCD23 structure 
reported in this thesis. Therefore, N269 was mutated for biophysical study and the 
mutants N269A and N269D were produced. Mutation of N269 in derCD23 does not 
weaken Ca2+ binding in ITC experiments, indicating that the crystal structure is correct. 
There is a mutation (G256S) close to the calcium binding site in the previous CD23 
double mutant structure, and this may be the reason for the N269 involvement in 
calcium binding in that structure.  
 
Comparison of the Ca2+-bound derCD23 structure with Ca2+-free derCD23 shows 
residues undergoing a conformational change upon Ca2+ binding. Calcium binding to 
derCD23 causes movement of T251, which drives P250 from the trans-conformation to 
the cis-conformation. Isomerisation of this conserved proline residue was also observed 
in mannose-binding protein (Ng et al., 1998). In addition, loop 4 was locked in a 
particular conformation that may be preferred for IgE binding. The role calcium plays in 














Putative Ca2+ “site 1” mutants (S252A, D258A) and “site 2” mutants (E249A, D270A) 
were studied by ITC, measuring their binding affinities for Ca2+ (see chapter 3). 
However, it is a common phenomenon to have unexpected secondary effects in such a 
mutagenesis study. Mutation of one residue may have an effect on other residues 
nearby, or even influence residues far from them. Thus, to complement the ITC 
experiments, it is informative to solve crystal structure of these mutants to see whether 
there are structural changes in addition to the mutated residues.  
 
Site directed mutagenesis was used to produce derCD23 mutant constructs, which were 
expressed and purified subsequently as described in chapter 2. 10 mg protein was 
typically obtained from 1 litre of cell culture for all mutants except S252A, which had a 
yield of 20 mg/litre.  
 
4.2 Crystallisation  
 
4.2.1 Initial crystallisation attempts 
 
Initially, all four mutants were set up for crystallisation in the similar conditions as 
wild-type derCD23 with no added calcium. However, only diffraction quality crystals 
of derCD23 mutant S252A were obtained. The other mutants did not give diffraction 
quality crystals. Then the structure and crystal packing of wild-type derCD23 was 
analyzed in COOT. This showed that only residue S252 of the four mutated residues 
has no interactions with residues in the same derCD23 molecule or other molecules 
around it in the crystal (Figure 4.1). The other three residues have no inter-molecular 
packing interactions either, but are all partially buried and involved in intra-molecular 
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interactions (Figure 4.1). It is therefore possible that derCD23 mutants E249A, D258A 




Figure 4.1 Putative Ca2+ site ligands E249, S252, D258 and D270 in the structure of wild-
type derCD23. 




4.2.2 Crystal screening 
 
The other three derCD23 mutants (E249A, D258A, D270A) at 5 mg/ml in 20 mM Tris 
pH 7.5, 125mM NaCl, were set up for crystal screening. Crystals of these three 
derCD23 mutants were obtained by the hanging drop vapour diffusion method from 
crystal screening at 18°C after two weeks. Crystals of mutant E249A were grown in 0.2 
M potassium thiocyanate, 0.1 M bis-tris-propane pH 8.5, 20% (w/v) PEG 3350, and 
20% glycerol was used as cryoprotectant prior to flash-cooling. Crystals of mutant 
D258A were produced in 18% ethanol, 4% PEG 400, 0.1 M sodium acetate pH 5.0, and 
25% glycerol was used as cryoprotectant. Crystals of mutant D270A were obtained in 
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30% PEG 4000, 0.3 M ammonium sulphate, and flash-frozen in liquid nitrogen using 
20% glycerol as croprotectant. 
 
 
Figure 4.2 Crystals of derCD23 mutants. 
Crystals of derCD23 mutants E249A (typically100×50×30 µm), S252A (60×30×20 µm), 
D258A (50×50×20 µm) and D270A (separated single crystal 160×60×20 µm). 
E249A in 0.2 M potassium thiocyanate, 0.1 M bis-tris-propane pH 8.5, 20% (w/v) PEG 3350. 
S252A in 18.5% PEG 6000, 2% 1,6-hexanediol, 0.05M ammonium sulphate, 0.1M sodium 
acetate pH 4.7. D258A in 18% ethanol, 4% PEG 400, 0.1 M sodium acetate pH 5.0. D270A in 
30% PEG 4000, 0.3M ammonium sulphate.  
 
 
4.3 Data collection and processing 
 
4.3.1 Data collection and processing 
 
Data from all crystals were collected at the Diamond Synchrotron using a q315 CCD 
detector, and processed using HKL2000 or MOSFLM. 
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 E249A S252A D258A D270A 
Space group P4122 P1 P65 P212121 
Unit-cell parameters 
(Å) 
a = 63.32 
b = 63.32 
c = 261.42 
α = 90.00 
β = 90.00 
γ = 90.00 
a = 52.50 
b = 56.87 
c = 62.68 
α = 68.06 
β = 88.23 
γ = 73.53 
a = 90.97 
b = 90.97 
c = 351.68 
α = 90.00 
β = 90.00 
γ = 120.00 
a = 73.78 
b = 109.11 
c = 139.00 
α = 90.00 
β = 90.00 
γ = 90.00 
Wavelength (Å) 0.9763 0.9795 0.9763 0.9795 
Resolution range 









Number of unique 
reflections 
25713 45157 36967 54601 
Redundancy 12.6 (13.0) 2.2 (2.1) 3.6 (3.5) 7.0 (6.7) 
Completeness (%) 100 (100) 97.1 (93.7) 91.6 (94.3) 99.7 (99.5) 
I/σ (I) 12.9 (2.3) 20.0 (2.0) 7.0 (1.9) 34.0 (4.0) 
Rmerge/pim (%) *2.0 (35.9) ^4.9 (36.9) *8.1 (40.0) ^7.8 (46.3) 
Table 4.1 Data collection and refinement statistics of derCD23 mutants. Values in 
parentheses are for the highest resolution shell. 
^Rmerge = ΣreflΣi|Ii - Iaver|/ΣreflΣiIi , where Ii is the intensity of a ith measurement of a reflection Iaver 
the average intensity for that reflection, calculated on all the measurements acquired for that 
reflection. Σrefl indicates the sum calculated over all the independent reflections measured.  
*Rpim= Σrefl(1/(nrefl -1))Σi|Ii - Iaver|/ΣreflΣiIi , where nrefl is the number of observations of reflection. 
 
 
4.3.2 Determination of space group and number of molecules in the asymmetric 
unit 
 
The space group and Matthews coefficient calculation of the four derCD23 mutants are 
shown in table 4.2. 
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 E249A S252A D258A D270A 
Space group P4122 P1 P65 P212121 
Molecules per 
asymmetric unit 















4.4 Structure solution, refinement and validation 
 
The structures of all mutants were solved by molecular replacement using PHASER 
with PDB 2H2T or 2H2R as the search model. In order not to bias the electron density 
map calculations, water molecules were removed from the search model.  
 
Manual model building was carried out with COOT, coupled with refinement using 
REFMAC5 and PHENIX. The progression of the refinement was monitored using R 
factors (Rwork and Rfree), and TLS refinement (Painter and Merritt, 2006) was 
implemented by finding TLS groups in PHENIX. NCS restraints were used to all chains 
and B-factor refinement was applied. Strategies and parameters used in the final stage 
of refinement are listed in Table 4.3. Protein atoms of the backbone were modeled first. 
SO42-, water and glycerol molecules were modeled according to electron density at a 
later stage using the Rfree as a guide. Only two disulphide bonds were found to be 
broken due to the radiation damage, and no calcium was modeled into any of the mutant 
structures (note that no calcium was present in the crystallisation buffer). Electron 
density was observed in calcium-binding site 2 of the S252A structure (chains A and 
B), and one water molecular was modeled into this site. Calcium ion was also tried, but 
it gave an unusually high B-factor value (100 Å2) compared with surrounding protein 
residues (40 Å2) and water molecules (35 Å2). Statistics of the refinement results of 
these four mutant structures are listed in Table 4.4. 
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 E249A S252A D258A D270A 
Refinement 
program 
REFMAC PHENIX REFMAC PHENIX 
B-factor 
refinement 
isotropic isotropic isotropic isotropic 
TLS groups one group for 
each chain 
 
chain A: 9 
chain B: 10 
chain C: 7 
chain D: 10 
one group for 
each chain 
 
chain A: 11 
chain B: 12 
chain C: 9 
chain D: 7 
chain E: 9 
chain F: 5 
chain G: 8 





for each chain 
- 
Table 4.3 Strategies and parameters used in the final stage of refinement of derCD23 
mutant structures. 
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 E249A S252A D258A D270A 
Protein residues 
































- chain D 
C160-C288 
(broken) 
- chain G 
C163-C174 
(half-broken) 
Water molecules 125 409 163 471 
Calcium ions - - - - 
SO42- - 4 - 25 
Glycerol  1 4 2 12 
Average B (Å2):     
Protein 31.6 40.4 51.0 43.5 
Water molecules 46.3 45.8 30.4 45.7 
Calcium ions - - - - 
Glycerol  42.1 61.7 60.9 67.8 
SO42- - 82.5 - 74.7 
Rwork/Rfree(%) 20.5/25.1 16.6/21.2 20.8/25.1 18.1/22.6 
r.m.s. deviations bond lengths = 
0.010 Å 
bond angles = 
1.375° 
bond lengths 
= 0.007 Å 
bond angles 
1.031° 





= 0.006 Å 
bond angles 
0.937° 
Table 4.4 Statistics of the refinement results of the final derCD23 mutant structures. 
Rwork = Σ||Fobs| - |Fcalc||/Σ|Fobs|, where Fobs and Fcalc are the observed and calculated structure 
factor amplitudes. 
Rfree = Σt||Fobs| - |Fcalc||/Σt|Fobs|, where Fobs and Fcalc are the observed and calculated structure 
factor amplitudes, and t is the test set of data omitted from refinement (5% in this case). 
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4.5 Structure analysis 
 
4.5.1 Overview of the derCD23 mutants structures 
 
Although the crystals of the four mutants have different space groups and numbers of 
molecules in the asymmetric unit (Figure 4.3), the structures are all very similar except 
for two loops (loop 1 and loop 4). There are no substantial effects of the mutations on 
other parts of the structure. Superimposition of wild-type derCD23 and all four mutant 
structures reveals large differences in loop 4 and small differences in loop 1. Calcium 
binding to derCD23 causes movement of calcium binding residues in “site 2”, 
isomerisation of P250 and changes in loop 4, as described in chapter 3. These structural 
changes can be used to compare the mutant structures with calcium-bound and -free 
structures. The structure of the S252A mutant displays two conformations of loop 4, 
which are similar to those seen in the calcium-free derCD23 structure. The structure of 
the E249A mutant shows a similar conformation for loop 4 as calcium-bound derCD23, 
while the D258A and D270A loop 4 structures are similar to the calcium-free 
conformation 2 (Figure 4.4).  
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Figure 4.3 Crystal structures of the four derCD23 mutant structures showing the contents 
of the asymmetric unit in each case. 
They have different numbers of molecules (3, 4, 8 and 7 respectively) in the asymmetric unit. 
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Figure 4.4 Superimposition of wild-type derCD23 structures with and without calcium, 
and all four mutant structures. 
 
 
4.5.2 Ca2+-binding site 
 
In chapter 3, ITC was used to measure the binding affinities of derCD23 mutants for 
calcium in order to determine the calcium binding site(s) and ligands. The crystal 
structures of these mutants were solved to see whether there are structural changes in 
addition to the mutated residues. Comparison of wild-type derCD23 and the four 
calcium site mutant structures indicate no substantial structural changes in the calcium 
binding site except for the mutations themselves (Figure 4.5). Calcium binding residues 
in these four mutant structures are in essentially the same positions as either the 
calcium-bound or calcium-free derCD23 structures. P250 is cis in conformation 1 and 
trans in conformation 2 in the structure of S252A, cis in E249A, and trans in the 
D258A and D270A structures (Table 4.5).  
 




Figure 4.5 Wild-type derCD23 with and without calcium and all four mutant structures, 
showing the calcium binding “site 2”.  
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 Number of molecules in 
the asymmetric unit 
P250 conformation 
Ca2+-bound 4 Cis 
Ca2+-free conformation1 2 Cis 
Ca2+-free conformation2 2 Trans 
E249A 3 Cis 
S252A conformation1 2 Cis 
S252A conformation2 2 Trans 
D258A 8 Trans 
D270A 7 Trans 
Table 4.5 Comparison of wild-type derCD23 with and without calcium, and all four 
mutant structures to show their P250 conformation.  
 
 
In the calcium-binding site of the D258A structure, R253 occupies the position for 
calcium binding in all eight molecules (Figure 4.6). This is a unique feature among all 
derCD23 and mutants structures. In the Ca2+-free CD23 double mutant structure, R253 
also points towards the calcium binding site but has different interactions with 
surrounding residues. In addition, in the D258A mutant, P250 adopts the trans 
conformation that is observed in the Ca2+-free derCD23 structure conformation 2. These 
two features, the location of R253 and the trans conformation of P250, may be the 
reason for the observed lack of binding affinity of this mutant to calcium in the ITC 
experiment, despite the fact that D258 is not a calcium-binding ligand in the calcium-
bound derCD23 structure. 
 
 
Chapter 4  Crystal structures of derCD23 Ca2+site mutants 	  
 100 
 
Figure 4.6 Ca2+-binding site in the structure of D258A. 
P250 adopts the trans conformation, and R253 occupies the position for calcium binding. This 
R253 interacts with the side chain of E249 and main chain of D270, which is probably another 
reason for the loss of binding ability to calcium in the ITC experiments (Section 3.10). 
 
 
4.6 SPR studies of wild-type derCD23 and mutants binding to IgE-Fc 
 
To investigate the role calcium plays in the binding of CD23 with IgE, surface plasmon 
resonance was used to characterize the interaction between wild-type derCD23 and the 
mutants with IgE-Fc. IgE-Fc was passed over immobilized wild-type derCD23 or the 
mutants (see chapter 2 for experimental details). The results are shown in Table 4.6 and 
Figure 4.7. In these SPR experiments, calcium increases CD23’s binding affinity to IgE 
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7-fold, which is consistent with previously published SPR data (Hibbert et al., 2005). In 
addition, calcium also increases S252A’s binding affinity to IgE 7-fold. S252A, N269A 
and N269D can bind calcium (as determined by ITC), therefore they are expected to 
behave in the same way as the binding of wild-type derCD23 to IgE-Fc. This is 
confirmed by the SPR data, although they present 2-fold higher or lower affinity 
compared with wild-type derCD23. Because E249A, D258A and D270A have lost the 
ability to bind calcium, they are expected to have the same binding affinity to IgE-Fc as 
calcium-free derCD23. In fact, E249A and D270A show binding affinities that are more 
similar to wild-type derCD23 in the presence of calcium than in the absence of calcium. 
A further surprising result is that the binding affinity between D258A and IgE-Fc is not 
measurable. However, we know that mutation of calcium binding site residues causes 
variation of the conformation of loop 4 (Figure 4.4), which is involved in binding to IgE 
(Chapter 5), and this may influence the binding of the calcium site mutants to IgE-Fc.  
 
 
 Ca2+(KD) No Ca2+(KD) 
WT 4.8±0.6x10-6 M 37.6±1.00x10-6 M 
S252A 2.5±0.4x10-6 M 16.8±0.60x10-6 M 
E249A 5.0±0.5x10-6 M No experiment 
D270A 11.1±2.2x10-6 M No experiment 
D258A Not measurable No experiment 
N269A 7.5±0.9x10-6 M No experiment 
N269D 10.8±1.2x10-6 M No experiment 
Table 4.6 SPR studies of the binding affinity of IgE-Fc to immobilised wild-type derCD23 
or mutants. 
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Figure 4.7 Surface plasmon resonance analysis of IgE-Fc binding to immobilized wild-type 
derCD23 and mutants. 
The binding was determined over a range of ligand concentrations: 62.5 (black), 125 (red), 250 




4.7 Summary and discussion 
 
This chapter describes the crystallisation and structure determination by X-ray 
crystallography of four derCD23 mutants. Surface plasmon resonance was used to 
characterize the interaction between wild-type derCD23 and the mutants with IgE-Fc. 
 
S252A was crystallised in similar conditions as wild-type derCD23. The three other 
derCD23 calcium binding site mutants (D258A, E249A, D270A) were crystallised in 
different conditions. They gave different space groups and numbers of molecules in the 
asymmetric unit. The overall structures of the four mutants are similar to the wild-type 
derCD23 structure, while loop 1 and loop 4 are observed in different conformations 
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(Figure 4.4). Calcium binding residues in these four mutant structures are in the same 
positions as either calcium-bound or calcium-free derCD23 structures (Figure 4.5). 
However, isomerisation of P250, shown in the calcium-free derCD23 structure, was 
also observed in the two conformations of the S252A structure. The other three mutants 
have only cis or trans-P250. It is possible that the mutations affect the isomerisation 
state of P250. Overall these structures indicate that mutation of calcium binding site 
residues has a substantial influence on loop 4, but little effect on other residues of the 
calcium binding site.  
 
In chapter 3, ITC experiments were used to determine the residues involved in calcium 
binding by measuring the binding affinity of the mutants to calcium. D258A was found 
to show no binding affinity with calcium, even though D258 is not a calcium ligand. 
The crystal structure now shows that the likely reason for this is the trans-P250 in 
D258A, which is not permissive for calcium binding. Also in the crystal structure of 
D258A, R253 occupies the position for calcium binding, which may be another reason 
for the lack of calcium binding to D258A.  
 
Surface plasmon resonance was used to characterize the interaction of wild-type 
derCD23 and the mutants with IgE-Fc. Calcium increases CD23’s binding affinity to 
IgE 7-fold, which is consistent with previous published SPR data (Hibbert et al., 2005). 
Calcium also increases 7-fold the IgE-binding affinity of S252A, which binds calcium 
with similar values as wild-type derCD23 and shows very similar structural features as 
calcium-free derCD23. S252A, N269A and N269D can bind calcium (as determined by 
ITC), therefore they behave as the binding of wild-type derCD23 to IgE-Fc.  However, 
some of the mutants show unexpected results in their binding affinities to IgE-Fc 
(Section 4.6). Although E249A and D270A have lost the ability to bind calcium, they 
show binding affinities that are more similar to wild-type derCD23 in the presence of 
calcium than in the absence of calcium. Furthermore, it is surprising that the binding 
affinity between D258A and IgE-Fc is not measurable. The reason may be the structural 
changes that occur in loop 4, which is involved in IgE binding (see chapter 5). 
 








IgE plays a central role in allergic diseases. CD23, the low-affinity IgE receptor, 
regulates IgE synthesis through interaction with membrane bound IgE and CD21, and is 
also involved in allergen presentation and transport (see chapter 1). Structural studies of 
the IgE/CD23 complex may reveal details of the molecular mechanism of allergic 
diseases and lead to CD23-targeted drug design.  
 
The first indication of the IgE binding site on CD23 came in 1989, with mutagenesis 
and monoclonal antibody binding studies which suggested residues 165-190 and 224-
256 were involved (Bettler et al., 1989; Bettler et al., 1992). In addition, the CD23 
binding site in IgE-Fc was located in the Cε3 domain (Nissim et al., 1991; Vercelli et 
al., 1989). NMR titration experiments by adding Cε3 to isotopically labelled derCD23 
showed residues W184, R188, Y189, A190, L198, H202, I221, G222, R224, N225, 
L226, W234, V235, A271, C273, D274, K276, and A279 in derCD23 were involved in 
binding to IgE (Figure 5.1) (Hibbert et al., 2005), and recently the site in Cε3 has been 
mapped by NMR with isotopically labelled Cε3 domain (Borthakur et al., 2012).  
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Figure 5.1 1H-15N chemical shift perturbation experiments define binding surfaces on 
derCD23 for Cε3 and CD21(D1-2). 
A and B: Example spectra of residues that show chemical shift perturbation on addition of Cε3 
or CD21(D1-D2). C: The binding site for Cε3 is coloured green and the binding site for CD21 
(D1-2) is coloured blue. (Figure taken from Hibbert et al., 2005) 
 
 
Six years ago, the group of Jardetzky tried to crystallise the complex of CD23 with 
Fcε3-4, but they only obtained crystals of CD23 (Wurzburg et al., 2006). However, the 
CD23 that they used is a double mutant. One of these mutations is G256S, which is on 
the IgE binding loop according to the previous mutagenesis study. Thus, this 
experiment was repeated using wild-type proteins (Fcε3-4 and derCD23), a different 
buffer, and mixing them in different ratios.  
 
After crystallisation of the complex of Fcε3-4 and derCD23, the structure was solved at 
3.1 Å resolution, but surprisingly it was found to have no calcium bound to it despite 
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the presence of 2 mM calcium in the crystallisation buffer (Dhaliwal et al., 2012). Then 
soaking and co-crystallisation with calcium were used to obtain the calcium-bound 
derCD23/Fcε3-4 structure. The co-crystallisation method gave higher resolution 
diffraction. This chapter presents the structure of this calcium-bound complex at a 
resolution of 3.3 Å. Comparison with the calcium-free derCD23/Fcε3-4 structure 




5.2.1 Crystallisation of “calcium-free” derCD23/Fcε3-4 complex 
 
Protein solution (0.22 mM Fcε3-4 and 0.44 mM derCD23 in 20 mM NaCl, 25 mM Tris 
7.5, 0.05% sodium azide, 4 mM CaCl2) was mixed 1:1 with precipitant for initial 
screening at 18°C using the hanging drop method. Crystals were obtained in about 10 
days in two conditions: MembFac F10 (0.2 M Sodium acetate trihydrate, 0.1 M Tris pH 
8.5, 15% PEG 4000) and Procomplex E5 (0.1 M Tris pH 8.0, 8% PEG8000). Crystals 
obtained from these two crystallisation conditions have different morphology (Figure 
5.2), but both of them diffract to about 3 Å resolution after optimization. Data were 
collected at the Diamond Synchrotron, and the structure of the complex was solved by 
Dr Balvinder Dhaliwal (Dhaliwal et al., 2012). No calcium was found to be present in 
the structure, which will be referred as the calcium-free complex. 
 
 
Figure 5.2 Crystals of the calcium-free derCD23/Fcε3-4 complex. 
Left: crystals grown in 0.2 M sodium acetate trihydrate, 0.1 M Tris pH 8.5, 15% PEG 4000; the 
longest dimension of a separated single crystal is 400 µm . Right: crystals grown in 0.1 M Tris 
pH 8.0, 8% PEG 8000; the longest dimension of a separated single crystal is 300 µm.  
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5.2.2 Crystallisation of calcium-bound derCD23/Fcε3-4 complex 
 
Initially, crystals obtained in the first condition (see section 5.2.1) were used for soaking 
with 10 mM CaCl2. However, the best crystal diffracted only to about 4 Å resolution. 
Therefore co-crystallisation with a high concentration of calcium was also performed to 
obtain the calcium-bound complex. The complex of derCD23 with Fcε3-4 (0.44 mM 
and 0.22 mM in 10 mM Tris pH 7.5, 20 mM NaCl, 0.05% sodium azide, 4 mM CaCl2) 
was mixed 1:1 with 0.2 M sodium acetate trihydrate, 0.1 M Tris pH 8.5, 16% PEG 4000 
and 10 mM CaCl2 with micro-seeding at 18°C. Crystals appeared after 8 days (Figure 
5.3), and were flash-frozen in liquid nitrogen using 25% glycerol, 0.1 mM Tris pH 7.5, 
16% PEG 4000, 0.2 M sodium acetate trihydrate and 15 mM CaCl2 as cryoprotectant. 
 
 
Figure 5.3 Crystals of the calcium-bound derCD23/Fcε3-4 complex.  
The longest dimension of a separated single crystal is 300 µm. 
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5.3 Data collection and processing  
 
5.3.1 Data collection and processing 
 
Data from all crystals were collected at the Diamond Synchrotron using a Pilatus 2M 
detector and radiation of wavelength λ= 0.9173 Å. The dataset for calcium-bound 
derCD23/Fcε3-4 with the highest resolution diffraction was used, and a summary of 
collection and processing of the derCD23/Fcε3-4 complex data is shown in Table 5.1. 
 
Space group P212121 
Unit-cell parameters (Å,degrees) a = 62.83 α = 90 
b = 110.13 β = 90 
c = 367.41 γ = 90 
Wavelength (Å) 0.9173 
Resolution range (highest shell) (Å) 73.5-3.30 (3.48-3.30) 
Number of unique reflections 33757 
Redundancy 4.9 
Completeness (%) 86.3 (84.0) 
I/σ (I) 5.1 (1.4) 
Rpim (%) 8.9 (50.1) 
Table 5.1 Data collection and processing statistics of derCD23/Fcε3-4 (Ca2+-bound). 
Values in parentheses are for the highest resolution shell. 
Rpim= Σrefl(1/(nrefl -1))Σi|Ii - Iaver|/ΣreflΣiIi , where nrefl is the number of observations of reflection 
 
 
5.3.2 Determination of space group and number of molecules in the asymmetric 
unit 
 
The space group (P212121) is the same, and cell parameters (a = 62.83Å, b = 110.13Å, c 
= 367.41Å, α = β = γ = 90°) are similar to the previously solved calcium-free 
derCD23/Fcε3-4 structure (Dhaliwal et al., 2012). The Matthews coefficient calculation 
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indicated the presence of three complexes (six derCD23 molecules and three Fcε3-4 
molecules) per asymmetric unit (Matthews coefficient 2.55Å3Da-1, 51.8% solvent). 
 
5.4 Structure solution and refinement 
 
5.4.1 Molecular replacement solution 
 
The structure of calcium-bound derCD23/Fcε3-4 was solved by molecular replacement 
using PHASER with the previously solved structure of calcium-free derCD23/Fcε3-4 
(PDB code 4EZM) as the search model. 
 
5.4.2 Model building and refinement 
 
Manual model building was carried out with COOT, coupled with refinement using 
REFMAC5 and PHENIX. The progression of the refinement was monitored using R 
factors (Rwork and Rfree), and TLS refinement was implemented using each of 12 chains 
as a group. The 12 chains are defined by letters as follows: chains A-F within the three 
Fcε3-4 molecules, and chains G-L for the six derCD23 molecules. The three complexes 
thus consist of A, B, G and H; C, D, I and J; and E, F, K and L chains. Local NCS 
restraints and isotropic B-factor refinement were used. Protein atoms and carbohydrate 
were modeled first. In the last stage, six calcium atoms were modeled, and no waters 
were added into the structure. Positive difference density in “site 2” of derCD23 
disappeared when calcium was modeled (shown for chain G in Figure 5.4). B-factor and 
the final refinement statistics are presented in Table 5.2.  
 
Some parts of the structure are poorly defined due to the low resolution. Electron 
density was observed for protein residues 335-386, and 389-545 of chain A; residues 
336-361, and 365-545 of chain B; residues 336-366, 372-420, and 429-545 of chain C; 
residues 335-364, 368-386, 390-453, 459-461, 464-480, 484-524, 527-541 of chain D; 
residues 335-366, 371-418, 423-428, 431-445, 450-478, 481-509, 520-540 of chain E; 
336-362, 365-445, 451-539 of chain F; residues 158-292 of chain G; residues 158-290 
of chain H; residues 158-291 of chain I; residues 158-292 of chain J; residues 157-
Chapter 5  Crystal structure of the Ca2+-bound derCD23/Fcε3-4 	  
 110 
291of chain K; residues 158-293 of chain L. N-linked carbohydrate chains with five 
sugar units ((NAG)2-(MAN)3) at N394 are present on five heavy chains, and seven 
sugar units ((NAG)2-)MAN)5) are visible on chain C. Details of the protein residues, 
calcium ions and carbohydrate units are shown in Table 5.3. 
 
 
Figure 5.4 Electron density maps in the region of the calcium binding “site 2”. 
The positive difference map (green in Figure A) disappeared when calcium (white cross in 
Figure B) was modeled in the calcium binding “site 2”. 
A: No calcium was modeled to calcium “site 2” of chain G. 2Fo-Fc (1σ	  level) electron density 
maps are shown in blue, Fo-Fc (3σ	  level) electron density maps are shown in red (negative but 
not visible) and green (positive). 
B: Calcium was modeled to calcium “site 2” of chain G. 2Fo-Fc (1σ	   level) electron density 
maps are shown in purple, and Fo-Fc (3σ	   level) electron density maps are shown in red 
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Number of:  
Protein atoms 15823 
Carbohydrate atoms 388 
Calcium ions 6 
Average B factors (Å2):  
Protein 150.0 
Carbohydrate 142.6 
Protein (chain A) 124.4 
Protein (chain B) 141.5 
Protein (chain C) 133.0 
Protein (chain D) 151.9 
Protein (chain E) 175.2 
Protein (chain F) 165.4 
Protein (chain G) 161.6 
Protein (chain H) 134.2 
Protein (chain I) 143.4 
Protein (chain J) 128.8 
Protein (chain K) 218.0 
Protein (chain L) 131.0 
Rwork/Rfree(%) 27.8/30.7 
r.m.s. deviations bond lengths = 0.015 Å 
bond angles = 1.775° 
Table 5.2 Statistics of the refinement process for calcium-bound derCD23/Fcε3-4 
structure. 
Rwork = Σ||Fobs| - |Fcalc||/Σ|Fobs|, where Fobs and Fcalc are the observed and calculated structure 
factor amplitudes. 
Rfree = Σt||Fobs| - |Fcalc||/Σt|Fobs|, where Fobs and Fcalc are the observed and calculated structure 
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Chain name Content 
Chain A: Fcε3-4 heavy chain: residues 335-386, 389-545; 
carbohydrate: ((NAG)2-(MAN)3)  
Chain B Fcε3-4 heavy chain: residues 336-361, 365-545; 
 carbohydrate: ((NAG)2-(MAN)3) 
Chain C Fcε3-4 heavy chain: residues 336-366, 372-420, 429-545; 
carbohydrate: ((NAG)2-(MAN)5) 
Chain D Fcε3-4 heavy chain: residues 335-364, 368-386, 390-453, 459-461, 
464-480, 484-524, 527-541;  
carbohydrate: ((NAG)2-(MAN)3) 
Chain E Fcε3-4 heavy chain: residues 335-366, 371-418, 423-428, 431-445, 
450-478, 481-509, 520-540; 
carbohydrate: ((NAG)2-(MAN)3) 
Chain F Fcε3-4 heavy chain: 336-362, 365-445, 451-539; 
carbohydrate: ((NAG)2-(MAN)3) 
Chain G derCD23: residues 158-292; one calcium 
Chain H derCD23: residues 158-290; one calcium 
Chain I derCD23: residues 158-291; one calcium 
Chain J derCD23: residues 158-292; one calcium 
Chain K derCD23: residues 157-291; one calcium 
Chain L derCD23: residues 158-293; one calcium 
Table 5.3 Protein residues of derCD23 and Fcε3-4, carbohydrate and calcium ions 
modelled into the structure. 
Six derCD23 molecules and six heavy chains of three Fcε3-4 molecules (AB, CD, EF) formed 














The refined structure was analysed with Molprobity as indicated in section 2.14. An 
analysis of the corresponding Ramachandran plot (Figure 5.5) showed that 99.4% of 
residues are in allowed regions of the plot. 
 
 
Figure 5.5 Ramachandran plots for the calcium-bound derCD23/Fcε3-4 structure, 
calculated with the Molprobity server. 
From the top left: plot of φ and ψ angles for the general case, glycine, proline and pre-proline 
residues. 99.1% of residues, indicated by small black circles, are in allowed (dark blue) regions. 
90.9% of residues are in the favoured (light blue) regions. 
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5.5 Overall structure of calcium-bound derCD23/Fcε3-4 
 
As for the previously solved calcium-free derCD23/Fcε3-4 structure (Dhaliwal et al., 
2012), three Fcε3-4 and six derCD23 molecules form 6 complex pairs in the 
asymmetric unit cell (Figure 5.6). All six derCD23 copies show calcium bound in “site 
2”, which affect interactions between derCD23 and Fcε3-4. However, the coordination 
of calcium is not shown clearly due to the limited resolution. Interpretable density is 
present for loop1 and loop 4 in all derCD23 molecules. The interface between chain D 
and chain J is the most clearly defined. 
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Figure 5.6 Cartoon representation of the Ca2+-bound derCD23/Fcε3-4 structure. 
A: showing all 12 chains of the 3 complexes, each with 2:1 derCD23: Fcε3-4. B: showing four 
chains of one complex with 2:1 derCD23: Fcε3-4. 
 
 
The angle between the Cε3 and Cε4 domains remains the same in the six Fcε3-4 heavy 
chains of the Ca2+-bound derCD23/Fcε3-4 structure (Figure 5.7 A), whereas slight 
derCD23 
Ca2+	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variations were observed in the Ca2+-free derCD23/Fcε3-4 (Dhaliwal et al., 2012). 
There are also no obvious differences between the six derCD23 head domains (Figure 
5.7 B), which was also found in the Ca2+-free derCD23/Fcε3-4.  
 
 
Figure 5.7 Comparison of derCD23 and Fcε3-4 in six complex pairs. 
A: The six Fcε3-4 heavy chains were superposed on the Cε4 domains of Chain A, and show no 
variation in the relative positions of the Cε3 domains. B: The superposed six derCD23 
molecules, showing virtually no structural variation. 
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5.6 Comparison of Ca2+-bound and -free derCD23/Fcε3-4 structures 
 
In the previously solved Ca2+-free derCD23/Fcε3-4 structure (Dhaliwal et al., 2012), 
derCD23 contacts Fcε3-4 using three salt bridges (D409-R188, E412-R188 and E412-
R224), a potential fourth salt bridge (E414-H186), four additional hydrogen bonds 
(R376-Y189, D409-Y189 and R440-S254 main chain and side chain interaction), and a 
few well-defined van der Waals interactions in all six interfaces. The buried surface 
area for each interaction between derCD23 and Fcε3-4 ranges from 860-920 Å2 for the 
six heavy-chain/derCD23 interactions. 
 
To investigate the role calcium plays in IgE binding, the Ca2+-bound complex was 
compared with the Ca2+-free derCD23/Fcε3-4 structure. The two derCD23/Fcε3-4 
complexes differ in two main respects according to a comparison made by 
superimposing all Cα atoms. Firstly, electron density attributable to Ca2+ is present in 
all 6 molecules of derCD23 at “site 2” in the Ca2+-bound derCD23/Fcε3-4 structure. 
They have similar arrangement of calcium site ligands in all derCD23 molecules. 
Secondly, large structural differences are observed in loop 4 of derCD23 that is 
involved in IgE binding. All 6 copies of loop 4 in the Ca2+-bound complex can be seen 
clearly, whereas 5 out of 6 copies of loop 4 in the Ca2+-free structure are disordered. 
The ordered loop 4 is seen only in the chain F/chain L interface of the Ca2+-free 
complex. New interactions between derCD23 and Fcε3-4 are observed by comparison 
of these two complexes.  
 
The most clearly defined interface between chain D and chain J in the Ca2+-bound 
complex is compared with the interface between chain D and chain J in the Ca2+-free 
complex, which has a disordered loop 4; it is also compared with the interface between 
chain F and chain L in the Ca2+-free complex, which has an ordered loop 4 (Table 5.4, 
Figure 5.9). Two new salt bridges between derCD23 and Fcε3-4, D227-R440 and 
D258-R440, are observed after calcium binding. The positively charged R440 in IgE 
protrudes into a deep pocket (Figure 5.9 and 5.10) that is mainly formed by D258 and 
D227 in derCD23. Electron density for these three residues is clearly observed at 1σ	  level	   in	   this 3.3 Å resolution structure (Figure 5.11). Other interactions between 
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derCD23 and Fcε3-4 are very similar compared with the Ca2+-free derCD23/Fcε3-4 
complex. Salt bridges and hydrogen bonds at the interface of chain D and chain J in the 
Ca2+-bound complex are shown in Figure 5.9. Most of the well-defined van der Waals 
interactions in the Ca2+-free complex (Dhaliwal et al., 2012) are also present in this 
Ca2+-bound complex. 
 
The buried surface area for each interaction between derCD23 and Fcε3-4 ranges from 
800-860 Å2 for the six interfaces (see chapter 2 for the tool used for calculation). This is 
less than the range of 860-920 Å2 in the calcium-free derCD23/Fcε3-4 structure 
(Dhaliwal et al., 2012). Because the interface between chain D and chain J is more 
clearly defined in the Ca2+-bound complex, this pair was used to measure the contact 
area contributed by Cε3, Cε4 and the linker region (residues 437-440) separately. The 
Cε3 contributes 66% to the contact area, while Cε4 and linker region contribute 13% 
and 21% respectively. The calcium-free derCD23/Fcε3-4 structure shows similar 
contribution of Cε3 (63%), Cε4 (12%) and the linker region (25%) to the contact area. 
 
Taken together, these results show that upon calcium binding loop 4 is stabilised and 
contributes new interactions between derCD23 and Fcε3-4. Comparison of 
uncomplexed derCD23 structures also reveals that loop 4 is locked in a particular 
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 Chain D and Chain J 
(Ca2+) interface 
Chain D and Chain J 
(No Ca2+) interface 
Chain F and Chain L 
(No Ca2+) interface 
Salt bridges D409-R188 D409-R188 D409-R188 
E412-R188 E412-R188 E412-R188 
E412-R224 E412-R224 E412-R224 
E414-H186 E414-H186 E414-H186 
R440-D227 - - 
R440-D258 - - 
Additional 
hydrogen bonds 
R376-Y189  R376-Y189  R376-Y189  
D409-Y189 D409-Y189 D409-Y189 
S437-C273 - S437-C273 
R440-Q255 - R440-Q255 
- R440-S254 (two) R440-S254 (two) 
Table 5.4 Interactions between derCD23 and Fcε3-4 in Ca2+-bound and -free 
derCD23/Fcε3-4 structures. 
 
Figure 5.8 A cartoon diagram overlay of Ca2+-free and Ca2+-bound derCD23/Fcε3-4 
complexes. 
Ca2+-bound structure (Chain D and Chain J) is shown in yellow, Ca2+-free (Chain F and Chain 
L, Dhaliwal et al., 2012) is shown in green. Conformational changes can be seen in loop 4.  
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Figure 5.9 Interfaces of Ca2+-free (pink) and Ca2+-bound (green) derCD23/Fcε3-4 
structures for chains D and J of the complexes. 
A: Interface of Ca2+-free derCD23/Fcε3-4 structure (pink). B: Interface of Ca2+-bound (green 
sphere) derCD23/Fcε3-4 structure (green). C: Superimposition of Ca2+-bound (green) and Ca2+-
free (pink) derCD23/Fcε3-4 structures. The side chains of residues in the interface are shown as 
sticks. The hydrogen bonds associated with salt bridges are shown as red dashes, additional 
hydrogen bonds are show as yellow dashes. 
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Figure 5.10 The positively charged R440 in IgE protrudes into a deep pocket that is 
mainly formed by D258 and D227 in derCD23. 
The Ca2+ bound structure of derCD23 (surface, chain J) and Fcε3-4 (cartoon, chain D) complex 
shows R440 in IgE pointing into a negative cavity in derCD23 formed by D227 and D258. 
R440 interacts with 3 residues in derCD23 by forming two salt bridges and a hydrogen bond. 
 
Figure 5.11 Electron density map showing R440 of IgE (chain D), D227 and D258 of 
derCD23 (chain J).  
The 2Fo-Fc map is contoured at 1.0 σ. This is the new salt bridge formed as a result of ordering 
loop 4 in derCD23 by calcium binding. 
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5.7 Summary and discussion 
 
IgE is the central player in allergic diseases (Gould and Sutton, 2008), and the 
interaction between CD23 and IgE may be a target for drug design. This chapter 
describes the crystallisation and structure determination by X-ray crystallography of the 
calcium-bound derCD23/Fcε3-4 complex to 3.3 Å resolution. The calcium-free 
derCD23/Fcε3-4 complex, previously solved at 3.1 Å resolution (Dhaliwal et al., 2012), 
is used for comparison with this calcium-bound complex. Structural comparison reveals 
the role calcium plays in CD23 binding to IgE. 
 
As a member of the CTLD superfamily, there are two putative calcium binding sites in 
CD23 according to sequence alignment. In the 2 Å resolution calcium-bound derCD23 
structure (described in chapter 3), three residues (E249, T251 and D270) in calcium 
binding  “site 2” and three water molecules are involved in the binding to Ca2+ (Figure 
3.13). No calcium is bound to “site 1”. The calcium-bound derCD23/Fcε3-4 structure 
confirms that calcium is bound to “site 2” in derCD23, despite not showing the 
coordination clearly due to the limited resolution. There is no evidence for a difference 
between the calcium co-ordination in the free and the IgE-bound derCD23. Most 
members of the CTLD superfamily possess a carbohydrate-binding activity that 
depends strictly on the binding of calcium (Ng et al., 1998). CD23 may have lost the 
function to bind carbohydrate, but calcium increases CD23’s binding affinity to IgE 7-
fold as determined by SPR (Hibbert et al., 2005). However, this calcium-bound 
complex indicates that calcium is not involved in IgE binding directly. What then is the 
role calcium plays in CD23 binding to IgE?  
 
In chapter 3, structural comparison of calcium-bound and -free derCD23 structures 
shows structural changes of loop 4 and loop 1 upon calcium binding to “site 2” in 
derCD23. In this chapter, this calcium-bound complex shows direct evidence of 
calcium-related structural changes in CD23 binding to IgE (Figure 5.8). Loop 4 of 
derCD23 is ordered in all six copies of derCD23 of the calcium-bound complex, 
whereas it is disordered in five out of six copies of the previously solved calcium-free 
complex (Dhaliwal et al., 2012). This indicates that the role calcium plays in IgE 
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binding is to stabilise loop 4. This is consistent with the comparison of calcium-bound 
and -free derCD23 structures. In addition, loop 4 of derCD23 in the calcium-bound 
complex with Fcε3-4 adopts a stabilised conformation, that although different to all the 
other observed conformations, is more like the conformation in the calcium-bound 
derCD23 structure alone than in the calcium-free structures. In contrast, the calcium-
free complex has a disordered loop 4 in 5 out of 6 derCD23 molecules, and the calcium-
free derCD23 structure has two conformations of loop 4 (Figure 5.12).  
 
Superposition of the six heavy chains of Fcε3-4 in the calcium-bound derCD23/Fcε3-4 
structure indicates that the angle between the Cε3 and Cε4 domains remains the same 
(Section 5.5), whereas slight variations are observed in the Ca2+-free derCD23/Fcε3-4 
(Dhaliwal et al., 2012). Thus, calcium bound to derCD23/Fcε3-4 may also stabilise the 
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Figure 5.12 Comparison of Ca2+-bound and -free derCD23 and derCD23/Fcε3-4 
structures. 
The stabilised loop 4 of derCD23 in the calcium-bound complex adopts a conformation that is 
more like the conformation in the calcium-bound derCD23 structure alone than the calcium-free 
structures. Both the calcium-free complex and calcium-free derCD23 structures have a more 
flexible loop 4, as the calcium-free complex has a disordered loop 4 in 5 out of 6 derCD23 
molecules and the calcium-free derCD23 structure has two conformations of loop 4. 
 
Importantly, the calcium-bound complex also shows new interactions between Fcε3-4 
and derCD23. R440 of IgE interacts with D258 and D227 of CD23 by forming two new 
salt bridges. In addition, different hydrogen bonds are observed between R440 of Fcε3-
4 and loop 4 of derCD23 (Table 5.4, Figure 5.9). Other interactions between Fcε3-4 and 
derCD23 remain the same in the two complexes. Surprisingly, calcium-bound 
derCD23/Fcε3-4 has a smaller buried surface area than the calcium-free complex 
(Section 5.6). D258, which is involved in the additional salt bridge in the calcium-
bound complex, is the only conserved residue of “site 1” in human CD23 according to 
sequence alignment, as described in chapter 3. However, no calcium binds to “site 1” in 
CD23. Taken together, it appears that human CD23 lost the function to bind calcium in 
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“site 1”, but evolved to bind protein (IgE) directly using “site 1” residue D258 when 
calcium is bound at “site 2”. 
 
In summary, the structure of the calcium-bound derCD23/Fcε3-4 complex reveals new 
protein-protein interactions, which explains the enhanced affinity in the presence of 
calcium. A comparison of the calcium-bound and -free derCD23, and the calcium-
bound and -free derCD23/Fcε3-4 complex structures reveals the role calcium plays in 
CD23 binding to IgE. The implications of these structural data will be discussed in 
more detail in the general discussion (Chapter 7). 	  	  	  	  	  	  	  	  








CD23, the low-affinity receptor of IgE, mediates many IgE-related immune responses 
by regulating IgE synthesis and presenting allergen to the immune system. Thus, 
targeting CD23 is a promising candidate therapy for the treatment of allergic diseases. 
Anti-CD23 antibodies could be used, according to recent studies. IDEC152 (also known 
as Lumiliximab) is a primatized, IgG1, anti-CD23 monoclonal antibody. Results of a 
phase I clinical trial with IDEC152 indicates this antibody is well tolerated and causes 
sustained and dose-dependent decreases of serum IgE level (Rosenwasser et al., 2003). 
Subsequently, IDEC152 was reported to be possibly involved in modulating antigen 
presenting cells and decreasing TH2-type immune responses (Poole et al., 2005). 
However, the mechanism of IDEC152 activity in allergic disease is not clear.  
 
Structural study of the complex of derCD23 and IDEC152 may reveal the mechanism 
of action of this antibody. In addition, determination of the derCD23/IDEC152 structure 
may also be helpful for developing new small-molecule CD23 inhibitors. This chapter 
describes digestion of IDEC152 IgG antibody, purification of the Fab and crystallisation 
of the complex of derCD23 and IDEC152-Fab. IDEC152 was donated by IDEC 
Pharmaceuticals, San Diego, CA, and the purification protocol of IDEC152-Fab was 
provided by Dr. Rebecca Beavil and Dr. Stella Fabiane (Section 2.9.2). 
 
6.2 Digestion of IDEC152 
 
Although 10 mg/ml IgG1 was expected to be digested at 37°C by papain in 4 hours, it 
was found that IDEC152 was not digested completely even when incubated overnight 
(Figure 6.1). Overnight digestion of IDEC152 was therefore used to make IDEC152-
Fab.  
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Figure 6.1 15% reducing SDS-PAGE of digested IDEC152 with time-scale.  
Lane 1-8: marker; 30 minutes digestion; 1 hour digestion; 2 hours digestion; 4 hours digestion; 
6 hours digestion; overnight digestion; 8 hours digestion. A: complete heavy chain; B: Fc heavy 
chain; C: Fab heavy chain and Fab light chain. 
 
 
6.3 Purification of IDEC152-Fab 
 
IDEC152-Fab was purified by ion exchange chromatography with the TSKgel SP-5PW 
glass column (Section 2.9.2). The purification profile of IDEC152-Fab is shown in 
Figure 6.2. Non-reducing SDS-PAGE indicates that the molecular weight of IDEC152-
Fab is about 50 kDa as expected (Figure 6.3).  
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Figure 6.2 Purification profile of IDEC152-Fab by ion exchange column. 
Fractions of B10-C6 were collected to run non-reduced SDS-PAGE. 
Blue curve: UV; Dotted blue curve: temperature; Brown curve: conductivity; Green curve: 




Figure 6.3 15% non-reducing SDS-PAGE indicates that the molecular weight of IDEC152-
Fab is about 50 kDa. 
Lane 1: marker; Lane 2-8: fractions B10-B4; Lane 9: fractions B3-B1; Lane 10: fractions C1-
C3; Lane 11: C4-C6.   
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6.4 Initial crystallisation trials for the complex of derCD23 and IDEC152-Fab 
 
Initially, 1.75 µl derCD23 at 20 mg/ml and 23.25 µl IDEC152-Fab at 4.37 mg/ml were 
mixed together at one to one ratio for crystallisation. Crystals of derCD23/IDEC152-
Fab complex were observed in 0.1 M Tris pH 8.0, 2.0 M ammonium sulfate after crystal 
screening at 18°C by the sitting drop vapour diffusion method (Figure 6.4). 
Optimization of crystallisation conditions was carried out by the micro-seeding method. 
Single crystals of the complex were obtained (Figure 6.5), which diffracted to about 3.5 
Å resolution at the Diamond Synchrotron. 
 
 
Figure 6.4 Crystals of derCD23/IDEC152-Fab complex. 
Crystals of derCD23/IDEC152-Fab complex in 0.1 M Tris pH 8.0, 2.0 M ammonium sulfate 
after screening. The longest dimension of the crystal clusters is 100 µm. 
Chapter 6                                                      The complex of derCD23 and anti-CD23 Fab (IDEC152-Fab) 	  
 130 
 
Figure 6.5 Crystals of derCD23/IDEC152-Fab complex. 
Crystals of derCD23/IDEC152-Fab complex in 0.1 M Tris pH 7.5, 1.8 M ammonium sulfate 




6.5 Crystallisation of purified derCD23/IDEC152-Fab complex 
 
6.5.1 Purification of derCD23/IDEC152-Fab complex 
 
The molecular weight of the derCD23/IDEC152-Fab complex (66.5 kD) is much higher 
than derCD23 (16.5 kD), but is close to IDEC152-Fab (50 kD). So it is more difficult to 
separate derCD23/IDEC152-Fab from IDEC152-Fab than derCD23 using a size 
exclusion column. Thus, derCD23 and IDEC152-Fab were mixed at 1.2 to 1 ratio, to 
form the complex before purification. After purification by size exclusion 
chromatography, fractions of two peaks were collected and characterized by SDS-
PAGE (Figure 6.6 and 6.7). Fractions of the complex were dialysed into the buffer (9 
mM Tris pH 7.5, 13.2 mM sodium acetate pH 5.06, 137.6 mM NaCl and 0.08% NaN3) 
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used for crystal screening. Then the purified complex was concentrated to the same 
concentration as used in initial crystal screening.  
 
 
Figure 6.6 Purification profile of the derCD23/IDEC152-Fab complex by size exclusion 
column.  






Figure 6.7 15% non-reducing SDS-PAGE indicates the first peak in Figure 6.6 (fractions 
14-16) is the derCD23/IDEC152-Fab complex. 
Lane 13-20: collected fractions (13-20) after size exclusion column; Control: the mixed 
derCD23 with IDEC152-Fab at 1.2 to 1 ratio. 
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6.5.2 Crystallisation of purified derCD23/IDEC152-Fab complex 
 
The purified derCD23/IDEC152-Fab complex was set up for crystallisation in 0.1 M 
Tris pH 7.5, 1.8 M ammonium sulfate. Crystals (Figure 6.8) obtained in this condition 




Figure 6.8 Crystals of derCD23/IDEC152-Fab complex. 
Crystals of derCD23/IDEC152-Fab complex in 0.1 M Tris pH 7.5, 1.8 M ammonium sulfate 
using purified complex. The longest dimension of the largest crystal is 200 µm. 
 
 
6.6 Summary and discussion 
 
This chapter describes the digestion of IDEC152, purification of IDEC152-Fab and 
crystallisation of the derCD23/IDEC152-Fab complex. The IDEC152-Fab was obtained 
by papain digestion of IDEC152 IgG antibody and purified using ion exchange 
chromatography. The crystal screening using mixed derCD23 and IDEC152-Fab at one 
to one ratio for conditions led to optimized crystals that diffracted to about 3.5 Å 
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resolution. Because derCD23 binds to IDEC152-Fab with high affinity (KA	  ≈	  109	  M-­‐1, 
Dr Balvinder Dhaliwal, unpublished data), it is possible to purify the 
derCD23/IDEC152-Fab complex for crystallisation.  The crystals of the purified 
complex diffracted to about 2.4 Å resolution.  
 
Quality of protein samples is important for the size and diffraction properties of 
crystals. Optimization is therefore required not only for crystal growth, but also for the 
purification of protein samples. This may be particularly important for crystallisation of 
protein complexes. 	  
The structure of this complex has been solved by Dr. Balvinder Dhaliwal, and a 
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Chapter 7: 
Summary and General Discussion 
 
 
Allergy is a modern disease that is mainly found in developed countries. IgE plays most 
important roles in allergic diseases (Sutton and Gould, 1993). It is well established that 
the role IgE plays in allergic diseases is through its interactions with two receptors: 
FcεRI (high-affinity Fc receptor) and CD23 (low-affinity Fc receptor). The best 
characterised function of IgE is performed by interaction with FcεRI on mast cells and 
basophils mediating immediate hypersensitivity, and on APCs (antigen-presenting cells) 
presenting allergen to the immune system. CD23 regulates IgE synthesis, and influences 
the activation and differentiation of B- and T-cells. CD23 also plays important roles in 
allergen presentation and transporting allergen-IgE complexes across epithelial barriers. 
The structure of IgE alone, and the complex with FcεRI have been described in detail 
(Holdom et al., 2011; McDonnell et al., 2001; Wan et al., 2002; Wurzburg et al., 2000). 
However, the structures of CD23 determined by NMR (Hibbert et al., 2005) and X-ray 
crystallography (Wurzburg et al., 2006) gave conflicting results concerning calcium 
binding sites, and no structural information on the IgE/CD23 complex had been 
reported. In addition, the role of calcium in CD23 binding to IgE remained to be 
resolved. 
 
IDEC152 is a primatized, IgG1, anti-CD23 monoclonal antibody, which decreases IgE 
level in serum in clinical trials (Rosenwasser et al., 2003) and inhibits allergen-induced 
responses in antigen-presenting cells and T cells (Poole et al., 2005). However, nothing 
is known of the structural details of IDEC152 binding to CD23. 
 
This thesis describes the crystal structures of Ca2+-bound wild-type derCD23, the 
complex with the Fcε3-4 sub-fragment of IgE-Fc, and four putative calcium binding site 
mutants of derCD23. Binding affinities of derCD23 and its mutants for calcium and for 
IgE-Fc were measured with ITC and SPR. The Fab fragment of IDEC152 IgG was 
prepared by enzymatic digestion from IDEC152 and crystals of the complex of 
derCD23 with IDEC152-Fab were grown, which diffracted to 2.4 Å resolution. 
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7.1 Calcium binding site in derCD23 
 
CD23 is a unique Ig receptor and belongs to the CTLD superfamily (Kikutani et al., 
1986; Kintner et al., 1981; Thorley-Lawson et al., 1986). Sequence alignment of Ca2+ 
site ligands in other C-type lectins and various species of CD23 suggested two putative 
Ca2+-binding sites in human CD23: a poorly conserved “site 1” and a well-conserved 
“site 2” (Figure 3.2). NMR titration experiments indicated Ca2+-binding to “site 1” 
(Hibbert et al., 2005), but Ca2+ was observed in “site 2” in the crystal structure of CD23 
double mutant (H213R and G256S) (Figure 3.3A) (Wurzburg et al., 2006).  
 
The crystal structure of Ca2+-bound derCD23 at 2 Å resolution shows that calcium binds 
to “site 2”, and has different coordination compared with the previously solved CD23 
double mutant crystal structure. Three residues (E249, T251 and D270) provide 4 
oxygen atoms and 3 water molecules provide 3 oxygen atoms involved in the binding of 
calcium. The geometry of the calcium coordination is pentagonal bipyramidal formed 
by the seven ligands (Section 3.7). The calcium-bound derCD23/Fcε3-4 structure 
(solved at 3.3 Å resolution) confirms that calcium is bound to “site 2”, although the 
coordination is not so clear due to the limited resolution. According to the alignment of 
CD23 sequences from various species, N269 is expected to be a calcium ligand, and is 
seen as such in the derCD23 double mutant structure. Surprisingly, N269 is not 
involved in the binding to Ca2+ in this derCD23 structure. Therefore, two mutations of 
N269 in derCD23 were designed in order to test this observation; it was found that 
neither mutation weakens calcium binding in ITC, indicating that N269 is not a calcium 
ligand. Calcium binding to derCD23 causes movement of T251, which drives P250 
from the trans-conformation to the cis-conformation. Isomerisation of this conserved 
proline residue from trans to cis for calcium-binding was also observed in mannose-
binding protein (Ng et al., 1998). The binding affinity of calcium to the other calcium 
binding site mutants of derCD23, measured by ITC, also supports the coordination of 
calcium, with the exception of the D258A mutation. Although this residue was excepted 
to bind calcium, since it is a “site 1” ligand, the crystal structure of this mutant shows 
that P250 is trans, the conformation not preferred for calcium-binding, and furthermore 
the R253 side chain occupies calcium binding “site 2” (Figure 4.6).  
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A possible reason for the different coordination in the previously solved crystal 
structure of CD23 double mutant (Wurzburg et al., 2006) is that one of the mutations, 
G256S, is close to the calcium binding “site 2”, and may cause changes in calcium 
coordination. Comparison of the structures of calcium-bound with calcium-free 
derCD23 also shows small variations in loop 1, which has two calcium binding “site 1” 
ligands. This is also consistent with the movement of loop 1 in the NMR titration 
experiments with calcium, which implied that calcium bound to “site 1” (Hibbert et al., 
2005).  
 
Carbohydrate binding is a fundamental function of some CTLDs, and this function is 
limited to calcium binding “site 2” for monosaccharides. But the presence of calcium in 
“site 2” does not guarantee carbohydrate binding (Zelensky et al., 2005). The human 
CD23 head domain has appearently lost the function to bind carbohydrate (Hibbert et 
al., 2005). The pentagonal bipyramidal geometry of the calcium coordination formed by 
seven ligands in CD23, instead of the eight ligands in most other carbohydrate binding 
CTLDs in “site 2”, may contribute to the lack of carbohydrate binding by the CD23 
head domain. The bisected apex consists of two water molecules in MBP, DC-SIGN 
and human asialoglycoprotin receptor-I (ASGPR-I) (Meier et al., 2000; Snyder et al., 
2005; Weis et al., 1992; Wurzburg et al., 2006), while two carbohydrate oxygen atoms 
occupied this bisected apex in these carbohydrate-bound lectins (Section 3.7). However, 
an N-linked sugar on domain 5 to 8 of human CD21 was reported to be involved in the 
CD23/CD21 interaction (Aubry et al., 1994). The mechanism for this is still not clear. 
 
7.2 The role calcium plays in CD23 binding to IgE 
 
CD23 regulates IgE synthesis through interaction with IgE and CD21. Structural studies 
of the IgE/CD23 complex may reveal details of the molecular mechanism of allergic 
diseases and lead to CD23-targeted drug design. Calcium increases derCD23 binding 
affinity to IgE-Fc 7-fold as determined in SPR experiments (Hibbert et al., 2005). This 
is confirmed by SPR data reported in this thesis. However, trimeric CD23 binding to 
IgE may be affected much more than 7-fold by calcium, due to the avidity effect 
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achieved by the three head domains. Wild-type derCD23 binds calcium with a KD = 1.5 
mM, and the concentration of calcium in human serum is about 2 mM (see chapter 3). 
This indicates that the calcium-bound and -free CD23 may be in an equilibrium that is 
sensitive to calcium concentration in physiological conditions. Slight changes of the 
concentration of calcium in the serum may have large effects on the binding of CD23 to 
IgE and this affect the regulation of IgE synthesis (Figure 1.7) and other IgE-dependent 
activities. Comparison of the structures of Ca2+-bound, -free derCD23 and 
derCD23/Fcε3-4 complexes reveals the role calcium plays in CD23 binding to IgE.  
 
Firstly, the Ca2+-bound derCD23/Fcε3-4 complex confirms that calcium binds to “site 
2”, and that calcium is not involved in the binding to IgE directly. This indicates that 
calcium increases the binding affinity of CD23 to IgE by influencing the structure of 
derCD23.  
 
Secondly, after calcium binding to derCD23 loop 4 is stabilised in a position that is 
preferred for CD23 binding to IgE. All 6 copies of loop 4 in the Ca2+-bound 
derCD23/Fcε3-4 complex are ordered, while 5 out of 6 copies of loop 4 in the Ca2+-free 
structure of the complex are disordered (Dhaliwal et al., 2012). Comparison of the 
structures of Ca2+-bound and Ca2+-free derCD23 also reveals that loop 4 is locked in a 
particular position after calcium binding. The Ca2+-bound derCD23 has only one 
conformation for loop 4, whereas two conformations are observed in Ca2+-free derCD23 
and some side chains (residues 253-254 in conformation 1) of loop 4 are disordered 
(Figure 5.12). Calcium-dependent isomerisation of P250 is also involved in the 
structural changes of loop 4 (Figure 3.15). In the earlier Ca2+-bound structure of CD23 
double mutant (Figure 3.3B), the disordered loop 4 (residues 253-257) is inconsistent 
with the role of Ca2+ in stabilizing the loop in other CTLDs (Ng et al., 1998; Sun, 
2006). A possible reason for this is the unpredicted effect caused by one of the 
mutations (G256S), which is part of loop 4 in derCD23.  
 
Thirdly, the Ca2+-bound complex reveals new interactions between derCD23 and Fcε3-
4. The Ca2+-bound derCD23/Fcε3-4 complex shows two new salt bridges (D258-R440 
and D227-R440) between derCD23 and Fcε3-4 after calcium binding (Figure 5.9). 
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According to an alignment of CD23 sequences in various species and some other C-type 
lectins, only human CD23 has a poorly conserved calcium binding “site 1” (Figure 3.2). 
D258 is the only conserved residue in the “site 1”, and D227 is a residue that lies 
between the poorly conserved N225 and K229 residues. It appears that human CD23 
lost the function to bind calcium in “site 1”, but evolved to bind protein (IgE) directly 
using “site 1” residue D258. 
 
In contrast with human CD23, the calcium binding “site 1” and “site 2” are both well 
conserved in mouse CD23, and may cause different binding ability of mouse CD23 to 
mouse IgE, and perhaps further different physiological roles in allergic diseases. In 
addition, mouse CD23 has a shorter stalk region than human CD23, stronger trimer 
formation and no C-terminal tail for the binding to CD21. All these differences need to 
be considered when mouse models are used to study the role of CD23 in allergic 
diseases. 
 
Finally, calcium bound to derCD23/Fcε3-4 may stabilise the angle between the Cε3 and 
Cε4 domains. Superposition of the six independent heavy chains of Fcε3-4 in the crystal 
structure of the calcium-free derCD23/Fcε3-4 complex shows slight variations between 
the Cε3 and Cε4 domains (Dhaliwal et al., 2012). However, the angle between the Cε3 
and Cε4 domains remains the same in all the six independent heavy chains in the Ca2+-
bound derCD23/Fcε3-4 structure (Section 5.5).  
 
7.3 Structures of putative calcium binding sites mutants  
 
Structures of the calcium binding sites mutants (E249A, S252A, D258A, D270A) of 
derCD23 were solved to see whether there are unexpected secondary effects in these 
mutagenesis experiments. Superimposition of wild-type derCD23 and all four mutant 
structures reveals large differences in loop 4, small differences in loop 1 and essentially 
the same positions of calcium binding residues (Figure 4.4 and Figure 4.5). These 
similar positions of calcium binding residues can explain the results of the ITC 
experiments to measure the binding affinity of calcium, with the exception of D258A. 
As described above (Section 7.1), the crystal structure of D258A shows that the side 
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chain of R253 moves to occupy the calcium “site 2”. 
 
Large structural differences in loop 4 may be the reason for the unexpected results of 
the binding affinity of some of these mutants to IgE-Fc by SPR. Calcium increases 
binding affinity of wild-type derCD23 and the S252A mutant to IgE-Fc 7-fold, which is 
consistent with previously published SPR data (Hibbert et al., 2005). S252A, N269A 
and N269D can bind calcium (as determined by ITC), therefore they behave in the same 
way as the binding of wild-type derCD23 to IgE-Fc.  However, some of the mutants 
show unexpected results in their binding affinities to IgE-Fc (Section 4.6). Although 
E249A and D270A lost the ability to bind calcium, they show binding affinities that are 
more similar to wild-type derCD23 in the presence of calcium than in the absence of 
calcium. It is also a surprise to see that the binding affinity between the D258A mutant 
and IgE-Fc is not measurable in the SPR experiments. One possible reason is disruption 
of the salt bridge, D258 of derCD23 with R440 of Fcε3-4, which is found in the 
calcium-bound derCD23/Fcε3-4 structure. Mutation of D258 may also influence other 
interactions in this region, such as R440 of Fcε3-4 with D227 and Q255 of derCD23. 
However, further study is needed to answer this question. 
 
7.4 The complex of derCD23 and IDEC152-Fab 
 
Chapter 6 reports the digestion of IDEC152 IgG, purification of IDEC152-Fab and 
crystallisation of the derCD23/IDEC152-Fab complex. The crystals of purified 
derCD23/IDEC152-Fab complex diffracted to higher resolution than those grown after 
mixing these two proteins together in the crystallisation drop. The structure of this 
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